var title_f9_3_9264="Cystic hygroma MRI II";
var content_f9_3_9264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An MR scan, T2-weighted spin echo sequence shows a cystic mass in the anterior mediastinum, which displaces the trachea and esophagus against the spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9264=[""].join("\n");
var outline_f9_3_9264=null;
var title_f9_3_9265="Hamstring strength testing with ER";
var content_f9_3_9265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hamstring strength testing with external rotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Performing strength testing of the hamstring with the leg externally rotated accentuates the stress placed upon the biceps femoris muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl Fields, MD; Spencer Copland, MD; and John Tipton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9265=[""].join("\n");
var outline_f9_3_9265=null;
var title_f9_3_9266="Foreign bodies B";
var content_f9_3_9266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of inorganic foreign bodies removed from children and adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9266=[""].join("\n");
var outline_f9_3_9266=null;
var title_f9_3_9267="Patient information: Viral gastroenteritis (The Basics)";
var content_f9_3_9267=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16941\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/62/32738\">",
"         Patient information: Dehydration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/13/27858\">",
"         Patient information: Rotavirus infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/1/27\">",
"         Patient information: Acute diarrhea in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/54/22371\">",
"         Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Viral gastroenteritis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/viral-gastroenteritis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H295108944\">",
"      <span class=\"h1\">",
"       What is viral gastroenteritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Viral gastroenteritis is an infection that can cause diarrhea and vomiting. It happens when a person&rsquo;s stomach and intestines get infected with a virus (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). Both adults and children can get viral gastroenteritis.",
"     </p>",
"     <p>",
"      People can get the infection if they:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Touch an infected person or a surface with the virus on it, and then don&rsquo;t wash their hands",
"       </li>",
"       <li>",
"        Eat foods or drink liquids with the virus in them. If people with the virus don&rsquo;t wash their hands, they can spread it to food or liquids they touch.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295108951\">",
"      <span class=\"h1\">",
"       What are the symptoms of viral gastroenteritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The infection causes diarrhea and vomiting. People can have either diarrhea or vomiting, or both. These symptoms usually start suddenly, and can be severe.",
"     </p>",
"     <p>",
"      Viral gastroenteritis can also cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A fever",
"       </li>",
"       <li>",
"        A headache or muscle aches",
"       </li>",
"       <li>",
"        Belly pain or cramping",
"       </li>",
"       <li>",
"        A loss of appetite",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have diarrhea and vomiting, your body can lose too much water. Doctors call this &ldquo;dehydration.&rdquo; Dehydration can make you have dark yellow urine and feel thirsty, tired, dizzy, or confused.",
"     </p>",
"     <p>",
"      Severe dehydration can be life-threatening. Babies, young children, and elderly people are more likely to get severe dehydration.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295108958\">",
"      <span class=\"h1\">",
"       Do people with viral gastroenteritis need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. Their doctor or nurse should be able to tell if they have it by learning about their symptoms and doing an exam. But the doctor or nurse might do tests to check for dehydration or to see which virus is causing the infection. These tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Tests on a sample of bowel movement",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295108966\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better or help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People with viral gastroenteritis need to drink enough fluids so they don&rsquo;t get dehydrated.",
"     </p>",
"     <p>",
"      Some fluids help prevent dehydration better than others:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Older children and adults can drink sports drinks.",
"       </li>",
"       <li>",
"        You can give babies and young children an &ldquo;oral rehydration solution,&rdquo; such as Pedialyte&reg;. You can buy this in a store or pharmacy. If your child is vomiting, you can try to give your child a few teaspoons of fluid every few minutes.",
"       </li>",
"       <li>",
"        Babies who breastfeed can continue to breastfeed.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with viral gastroenteritis should avoid drinking juice or soda. These can make diarrhea worse.",
"     </p>",
"     <p>",
"      If you can keep food down, it&rsquo;s best to eat lean meats, fruits, vegetables, and whole-grain breads and cereals. Avoid eating foods with a lot of fat or sugar, which can make symptoms worse.",
"     </p>",
"     <p>",
"      Do NOT take anti-diarrhea medicines (medicines to stop diarrhea), or give these medicines to your child. These medicines can make the infection last longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295108973\">",
"      <span class=\"h1\">",
"       Should I call the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call the doctor or nurse if you or your child:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Has any symptoms of dehydration",
"       </li>",
"       <li>",
"        Has diarrhea or vomiting that lasts longer than a few days",
"       </li>",
"       <li>",
"        Vomits up blood, has bloody diarrhea, or has severe belly pain",
"       </li>",
"       <li>",
"        Hasn&rsquo;t had anything to drink in a few hours (for children), or in many hours (for adults)",
"       </li>",
"       <li>",
"        Hasn&rsquo;t needed to urinate in the past 6 to 8 hours (during the day), or if your baby or young child hasn&rsquo;t had a wet diaper for 4 to 6 hours",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295108980\">",
"      <span class=\"h1\">",
"       How is viral gastroenteritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people do not need any treatment, because their symptoms will get better on their own. But people with severe dehydration might need treatment in the hospital for their dehydration. This involves getting fluids through an &ldquo;IV&rdquo; (a thin tube that goes into the vein).",
"     </p>",
"     <p>",
"      Doctors do not treat viral gastroenteritis with antibiotics. That&rsquo;s because antibiotics treat infections that are caused by bacteria &ndash; not viruses.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295108987\">",
"      <span class=\"h1\">",
"       Can viral gastroenteritis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. To lower the chance of getting or spreading the infection, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands with soap after you use the bathroom or change your child&rsquo;s diaper, and before you eat.",
"       </li>",
"       <li>",
"        Avoid changing your child&rsquo;s diaper near where you prepare food.",
"       </li>",
"       <li>",
"        Make sure your baby gets the",
"        <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42789?source=see_link\">",
"         rotavirus vaccine",
"        </a>",
"        . Vaccines are treatments that can prevent serious infections. Rotavirus is a virus that commonly causes viral gastroenteritis in children.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H295109051\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       Patient information: Dehydration (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=see_link\">",
"       Patient information: Rotavirus infection (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       Patient information: Acute diarrhea in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"       Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/3/9267?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16941 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-447D2A5374-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9267=[""].join("\n");
var outline_f9_3_9267=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295108944\">",
"      What is viral gastroenteritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295108951\">",
"      What are the symptoms of viral gastroenteritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295108958\">",
"      Do people with viral gastroenteritis need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295108966\">",
"      Is there anything I can do on my own to feel better or help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295108973\">",
"      Should I call the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295108980\">",
"      How is viral gastroenteritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295108987\">",
"      Can viral gastroenteritis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H295109051\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=related_link\">",
"      Patient information: Rotavirus infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9268="Erwinia asparaginase: Patient drug information";
var content_f9_3_9268=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Erwinia asparaginase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/39/12917?source=see_link\">",
"     see \"Erwinia asparaginase: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13388919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Erwinaze&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13382001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Erwinase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13392994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13392993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701552",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to asparaginase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug caused bleeding, a blood clot, or an irritated pancreas before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13392998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatic disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13392999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13393000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13392996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13393002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17099 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9268=[""].join("\n");
var outline_f9_3_9268=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13388919\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382001\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13392994\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13392993\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13392998\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13392999\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13393000\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13392996\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13393002\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/39/12917?source=related_link\">",
"      Erwinia asparaginase: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9269="Oxymetholone: Patient drug information";
var content_f9_3_9269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxymetholone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10868?source=see_link\">",
"     see \"Oxymetholone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anadrol&reg;-50",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may change cholesterol levels and raise your chance of heart disease. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691725",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxymetholone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Prostate cancer, very bad kidney disease, or very bad liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman and have breast cancer with high calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698664",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, a deep voice, facial hair, pimples, or period changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11858 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-E2FE460E4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9269=[""].join("\n");
var outline_f9_3_9269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205251\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027925\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027927\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027926\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027931\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027932\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027934\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027929\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027930\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027935\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027936\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/39/10868?source=related_link\">",
"      Oxymetholone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9270="Clodronate: Drug information";
var content_f9_3_9270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clodronate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/11/16565?source=see_link\">",
"    see \"Clodronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F152938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bonefos&reg;;",
"     </li>",
"     <li>",
"      Clasteon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F152955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bisphosphonate Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F152941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypercalcemia of malignancy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clasteon&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single infusion: 1500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Multiple infusions: 300 mg once daily; treatment duration should not exceed 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bonefos&reg;: Multiple infusions: 300 mg once daily; treatment duration should not exceed 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Recommended daily maintenance dose following I.V. therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clasteon&reg;: Range: 1600 mg (4 capsules) to 2400 mg (6 capsules) given in a single or 2 divided doses; maximum recommended daily dose: 3200 mg (8 capsules).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bonefos&reg;: Range: 1600 mg (4 capsules) to 2400 mg (6 capsules) given in single or 2 divided doses; maximum recommended daily dose: 3200 mg (8 capsules).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Osteolytic bone metastases:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clasteon&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Single infusion: 1500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Multiple infusions: 300 mg once daily; treatment duration should not exceed 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bonefos&reg;: Multiple infusions: 300 mg once daily; treatment duration should not exceed 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clasteon&reg;: Recommended daily maintenance dose following I.V. therapy: Range: 1600 mg (4 capsules) to 2400 mg (6 capsules) given in a single or 2 divided doses; maximum recommended daily dose: 3200 mg (8 capsules).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bonefos&reg;: Initial: 1600 mg/day; may be increased to a maximum of 3200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Retreatment: Limited data suggests that patients who develop hypercalcemia following discontinuation of therapy or during oral therapy may be retreated with Bonefos&reg; or Clasteon&reg; at a higher oral dosage (up to 3200 mg/day) or by I.V. infusion with Clasteon&reg; (1500 mg as single dose or 300 mg once daily) or Bonefos&reg;  (300 mg once daily).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F152942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Clasteon&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum creatinine (S",
"     <sub>",
"      cr",
"     </sub>",
"     ) &gt;5 mg/dL: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;2.5-5 mg/dL: Dosage reduction is recommended; however, there are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bonefos&reg;:",
"     <b>",
"      Note:",
"     </b>",
"     S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;5 mg/dL: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     : 50-80 mL/minute: Administer 75% to 100% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     : 12-49 mL/minute: Administer 50% to 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     : &lt;12 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Daily doses &gt;1600 mg should not be used continuously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     : &gt;50 mL/minute: No dosage reduction recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     : 30-50 mL/minute: Administer 75% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     : &lt;30 mL/minute: Administer 50% of normal dose.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F6006757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bonefos&reg;, Clasteon&reg;: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bonefos&reg;: 60 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clasteon&reg;: 30 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F152917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules: Administer with a glass of plain water at least 2 hours (Bonefos&reg;) or 1 hour (Clasteon&reg;) before or after food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Do not administer as bolus injection; for single infusion therapy administer over at least 4 hours; for multiple-infusion therapy administered once daily, infuse over 2-6 hours. Patients should be adequately hydrated with oral or I.V. fluids prior to infusion.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F152961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W or 0.9% NS.",
"     <b>",
"      Incompatible",
"     </b>",
"     with calcium-containing solutions (eg, Ringer&rsquo;s solution).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F152916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hypercalcemia of malignancy; management of osteolysis due to bone metastases of malignancy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F152953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Hepatic: Transaminases increased (&le;18%; &gt;2 x ULN: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: GI disturbances (&le;10%; includes anorexia, diarrhea, gastric pain, nausea, vomiting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Serum creatinine increased (1%), BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, bronchospasm (patients with aspirin-sensitive asthma), dysphagia, erythematous rash, hypersensitivity reactions (angioedema, pruritus, rash, respiratory disorder, urticaria), hypophosphatemia (transient), leukemia/myelodysplasia (rare), macropapular rash, mouth irritation, musculoskeletal pain (severe), oliguria, osteonecrosis (primarily of jaw), parathyroid hormone increased, proteinuria, renal failure, ulcerative pharyngitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F152920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clodronate, bisphosphonates, or any component of the formulation; severe GI inflammation; renal impairment (serum creatinine &gt;5 mg/dL, SI 440 micromole/L); concomitant use with other bisphosphonates; pregnancy or breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F152903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone/joint/muscle pain: Infrequently, severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Risk of hypocalcemia (often asymptomatic) may be associated with both oral and intravenous use, however chelation of serum calcium observed with intravenous administration can further increase this risk. Interrupting the infusion or reducing the oral dose may be necessary. Correction of severe or symptomatic hypocalcemia may require calcium supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw (ONJ): Bisphosphonate therapy has been associated with osteonecrosis, primarily of the jaw; this has been observed mostly in cancer patients, but also in patients with postmenopausal osteoporosis and other diagnoses. Risk factors include a diagnosis of cancer, with concomitant chemotherapy, radiotherapy, or corticosteroids; anemia, coagulopathy, infection, or pre-existing dental disease. Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. Symptoms included nonhealing extraction socket or an exposed jawbone. Some experts suggest that there is no evidence that discontinuing therapy reduces the risk of developing ONJ (Assael, 2009). As a precautionary measure, dental exams and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. Invasive dental procedures should be avoided during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Dose reductions, close monitoring of serum creatinine and BUN, and adequate hydration are required with renal dysfunction. Use is contraindicated when serum creatinine &gt;5 mg/dL (SI 440 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Dilute prior to use; adequate hydration should be ensured prior to infusion; avoid infiltration/extravasation. May cause hypocalcemia or transient hypophosphatemia. Do not give as bolus injection (may precipitate acute renal failure, severe local reactions, and thrombophlebitis). Monitor renal function during and after intravenous administration. Interrupt infusion in patients experiencing deteriorating renal function during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Clodronate may increase the serum concentration of Estramustine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F152934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: All food and beverages may interfere with absorption. Coadministration with dairy products may decrease absorption. Beverages (especially orange juice and coffee), food, and medications (eg, antacids, calcium, iron, and multivalent cations) may reduce the absorption of bisphosphonates as much as 60%.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F152923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bisphosphonates have been shown to cross the placenta and cause embryo/fetal effects in animals. Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. There are no adequate and well-controlled studies in pregnant women; use is contraindicated during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F152947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10164344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at least 1 hour (Clasteon&reg;) or 2 hours (Bonefos&reg;) before or after food.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F152911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes including calcium, phosphorous, magnesium, and potassium; monitor for hypocalcemia for at least 2 weeks after therapy; serum creatinine, BUN, CBC with differential, hepatic function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F152915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium (total): Adults: 9.0-11.0 mg/dL (SI: 2.05-2.54 mmol/L), may slightly decrease with aging; Phosphorus: 2.5-4.5 mg/dL (SI: 0.81-1.45 mmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F152924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actabone (ID);",
"     </li>",
"     <li>",
"      Bonefos (AT, BE, BG, BR, CH, CL, CO, CZ, DK, EE, ES, FI, GB, GR, HK, HN, ID, IE, IL, MX, MY, NL, NO, PE, PH, PK, PL, RU, SE, SG, TH, TR, TW);",
"     </li>",
"     <li>",
"      Clasteon (IT);",
"     </li>",
"     <li>",
"      Clodron (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F152902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A bisphosphonate which lowers serum calcium by inhibition of bone resorption via actions on osteoclasts or on osteoclast precursors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F152919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of calcium-lowering effects: I.V.: Within 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of calcium-lowering effects: 5 days to 3 weeks following discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid but low absorption (~1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~20 L; 20% of absorbed clodronate is bound to bone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Variable (2% to 36%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 1% to 3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Oral: ~6 hours; I.V.: 13 hours (serum); prolonged in bone tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (60% to 80% of absorbed dose as unchanged drug); feces (as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy: Expert Panel Recommendations,&rdquo;",
"      <i>",
"       JADA",
"      </i>",
"      , 2006, 137(8):1144-50. Available at file://jada.ada.org/cgi/content/full/137/8/1144",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/16873332/pubmed\" id=\"16873332\" target=\"_blank\">",
"        16873332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assael LA, &ldquo;Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/19371813/pubmed\" id=\"19371813\" target=\"_blank\">",
"        19371813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Durie BG, Katz M, and Crowley J, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(1):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/16000365/pubmed\" id=\"16000365\" target=\"_blank\">",
"        16000365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filleul O, Crompot E, and Saussez S, \"Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,\"",
"      <i>",
"       J Cancer Res Clin Oncol",
"      </i>",
"      , 2010, 136(8):1117-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/20508948/pubmed\" id=\"20508948\" target=\"_blank\">",
"        20508948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maerevoet M, Martin C, and Duck L, &ldquo;Osteonecrosis of the Jaw and Bisphosphonates,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(1):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/16003838/pubmed\" id=\"16003838\" target=\"_blank\">",
"        16003838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMahon RE, Bouquot JE, Glueck CJ, et al, &ldquo;Osteonecrosis: A Multifactorial Etiology,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2004, 62(7):904-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/15244000/pubmed\" id=\"15244000\" target=\"_blank\">",
"        15244000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruggiero SL, Dodson TB, Assael LA, et al, &ldquo;American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws-2009 Update,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):2-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/19371809/pubmed\" id=\"19371809\" target=\"_blank\">",
"        19371809",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tarassoff P and Csermak K, &ldquo;Avascular Necrosis of the Jaws: Risk Factors in Metastatic Cancer Patients,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2003, 61(10):1238-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/3/9270/abstract-text/14586868/pubmed\" id=\"14586868\" target=\"_blank\">",
"        14586868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8774 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9270=[""].join("\n");
var outline_f9_3_9270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152938\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152955\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152941\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062976\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152942\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6006757\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217381\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152917\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152961\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152916\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152953\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152920\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152903\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299064\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152907\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152934\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152923\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152947\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10164344\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152911\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152915\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152924\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152902\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152919\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/11/16565?source=related_link\">",
"      Clodronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9271="Bees, yellow jackets, hornets, and wasps: Biology and identification";
var content_f9_3_9271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bees, yellow jackets, hornets, and wasps: Biology and identification",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9271/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9271/contributors\">",
"     Nancy L Breisch, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9271/contributors\">",
"     Albert Greene, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9271/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9271/contributors\">",
"     David B Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9271/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9271/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/3/9271/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stinging Hymenoptera are taxonomically divided into three principal groups: ants, bees, and wasps. The majority of allergic reactions to stings are due to this order of insects. This topic reviews the biology and identification of the flying Hymenoptera that include bees, yellow jackets, hornets, and wasps. Avoidance of the flying Hymenoptera is discussed separately, as are fire ants, which are also members of the Hymenoptera order. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/22/6502?source=see_link\">",
"     \"Bees, yellow jackets, hornets, and wasps: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7752?source=see_link\">",
"     \"Entomology and control of imported fire ants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosis and management of stinging insect allergy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=see_link\">",
"     \"Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=see_link\">",
"     \"Diagnosis of Hymenoptera venom allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=see_link\">",
"     \"Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=see_link\">",
"     \"Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous misconceptions about Hymenoptera taxonomy, biology, stinging behavior, and sting avoidance are widespread throughout the clinical literature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/1\">",
"     1",
"    </a>",
"    ]. This is due partly to the repeated citation of references written by non-entomologists containing fundamental errors, and partly to the extensive use of common names for these insects, such as \"bee\", \"wasp\", and \"hornet\". These informal expressions are often used imprecisely by clinicians, as well as the general public. However, biologists have long adhered to a set of specific meanings for the most frequently used insect common names, as well as a standardized peer review process to create new ones [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. These familiar terms, when used correctly, can facilitate communication between clinicians and their patients.",
"   </p>",
"   <p>",
"    This topic review will adhere to the well-established entomologic convention that calls the aculeus (ie, a modified ovipositor used as a venom-injection device) a \"sting,\" although the colloquial term is \"stinger\" [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. No male Hymenoptera can sting, because the aculeus is a female organ.",
"   </p>",
"   <p>",
"    The stinging Hymenoptera are taxonomically divided into three principal groups: ants, bees, and wasps. Only bees and wasps will be discussed here.",
"   </p>",
"   <p>",
"    The most important aspects of bee and wasp biology, from a clinical standpoint, involve two principal dichotomies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first major distinction is that of eusocial (highly social) versus solitary or primitively social species. Most bees and wasps are solitary, meaning that a single female builds a nest, without assistance, to rear her brood of new males and females. The purpose of her sting is for intraspecific competition over nest resources, self-defense against predators, and (in the case of solitary wasps) prey capture [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. These insects will not sting to protect their nest and present no hazard to humans under most circumstances.",
"      <br/>",
"      <br/>",
"      A relatively few bee and wasp species are eusocial. A female (termed a \"queen\") uses her sterile daughters (termed \"workers\") to build a nest and rear a colony of additional workers, which eventually rear a brood of new males and reproductive females. Worker bees and wasps will readily sting in defense of their nest if they perceive it is threatened, unlike solitary or primitively social species. They will also sting in self-defense [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/5,8\">",
"       5,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second dichotomy involves the two circumstances under which worker bees and wasps use their stings. Humans most often are stung because of accidental contact with an individual worker that is foraging for food, water, or building materials away from its nest. This lone worker delivers a single, reflexive sting in defense of its life. In contrast, disturbing a nest, or being in the vicinity of a disturbed nest, may lead to multiple stings from its alarmed workers, even if the nest itself is not directly contacted. These two sets of circumstances present completely different risk factors requiring different types of avoidance measures [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIOLOGY AND IDENTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For simplicity, this topic review will refer to the eusocial bees and wasps that constitute the major stinging threat to humans as \"social\" and the remaining species as \"solitary\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Social bees",
"    </span>",
"    &nbsp;&mdash;&nbsp;All social bees are classified in the family, Apidae. In general, bees are distinguished from other Hymenoptera by their collection of pollen as the protein source for their larvae. Social bees also feed their larvae honey, which they manufacture from collected floral nectar. Their nests are made of wax, which the bees secrete from glands on their abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The term \"hive\" is properly used only for manmade containers that house domesticated bees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Bumble bees",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bumble bees are robust, easily recognized bees with a dense coat of black and yellow (or occasionally orange and white) fur (",
"    <a class=\"graphic graphic_picture graphicRef73585 \" href=\"UTD.htm?6/61/7125\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"     table 1",
"    </a>",
"    ). There are 49 bumble bee species in the United States, all of which belong in the genus Bombus. Colonies last only one season, are typically rather small (usually less than 50 workers), and often located in old rodent burrows or other cavities that are not prone to human disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Honey bees",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout much of the world, the name \"honey bee\" refers to a single species, Apis mellifera. This species evolved in tropical Africa and was widely bred by humans into numerous subspecies (",
"    <a class=\"graphic graphic_picture graphicRef62810 \" href=\"UTD.htm?34/3/34869\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. Other than in its native region, all colonies living in natural circumstances are considered feral, in that they have originated from domesticated lineages. Unlike bumble bees and most social wasps, honey bee colonies are able to survive temperate winters because of their stored honey and heat-producing clustering behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Members of the genus Apis are well-known for their sting autotomy, in which the sting anchors in vertebrate flesh by means of harpoon-like barbs, is spontaneously torn from the abdomen by the bee's own escape efforts, and continues to inject venom into the victim [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]. The bee invariably dies from its wounds.",
"   </p>",
"   <p>",
"    Honey bee colonies range from 40,000 to 80,000 workers. Accidental disturbance of feral colonies in the United States was rare until the 1990s because nests were typically located within tree cavities or structural voids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The arrival of Africanized honey bees (hybrids of various domestic honey bees with the African subspecies Apis mellifera scutellata) in 1990 markedly increased the stinging risk for people and domestic animals over much of the South (",
"    <a class=\"graphic graphic_algorithm graphicRef80397 \" href=\"UTD.htm?24/14/24815\">",
"     algorithm 1",
"    </a>",
"    ), since these bees establish nests in a wide variety of locations that are readily subject to human disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In addition, this bee has an extremely low defensive response threshold and is capable of some of the most severe attacks known for any social insect. This hyper-defensive behavior has earned them the alarmist title of \"killer bees\" by the popular media. Africanized bees are indistinguishable in appearance and venom chemistry from typical \"European\" honey bees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Solitary bees",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several families of bees, including Apidae, contain solitary species. Most are innocuous, although a few occasionally come to the attention of clinicians either because of unusual stinging incidents or patient concerns due to their appearance.",
"   </p>",
"   <p>",
"    Sweat bees are tiny bees in the family Halictidae that are attracted to human perspiration (",
"    <a class=\"graphic graphic_picture graphicRef77442 \" href=\"UTD.htm?15/5/15443\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"     table 1",
"    </a>",
"    ). They often sting when accidentally pressed. These bees can be an annoying nuisance, but are dangerous only to those who are allergic to their venom.",
"   </p>",
"   <p>",
"    Carpenter bees (Apidae) are large bees that bore into structural wood and bear a superficial resemblance to bumble bees (",
"    <a class=\"graphic graphic_picture graphicRef74723 \" href=\"UTD.htm?22/25/22931\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"     table 1",
"    </a>",
"    ). The territorial males may aggressively hover close to people, but are completely harmless.",
"   </p>",
"   <p>",
"    Mining or digger bees (Andrenidae and Apidae) may be abundant where soil conditions favor burrow construction. As with carpenter bees, most of the individuals flying back and forth in these aggregations are harmless males [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Social wasps",
"    </span>",
"    &nbsp;&mdash;&nbsp;All social wasps are classified in the family Vespidae, which also includes some solitary forms. The two medically important subfamilies are the Vespinae (commonly known in the United States as yellow jackets and hornets) and the Polistinae (commonly referred to as paper wasps). Members of both subfamilies construct distinctive nests out of wood fibers scraped from either sound (eg, fence posts) or rotted (eg, decaying logs) sources and mixed with saliva to form a paper-like material. Unlike bees, the protein source for larval growth is live arthropod prey subdued with the mandibles (not the sting). Some pestiferous yellow jacket species scavenge carrion or human food. Colonies of social wasps normally last for only one season and die out in the fall and winter in temperate regions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the more enduring myths in the clinical and popular literature is that wasp stings are \"smooth\", in contrast to the honey bee, enabling the insect to sting repeatedly. In fact, the stings of virtually all social wasps are barbed to some degree and sting autotomy has been recorded for many more (mostly tropical) wasp species than for bees [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/21\">",
"     21",
"    </a>",
"    ]. However, most species of wasps can withdraw and reinsert their sting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Yellow jackets and hornets",
"    </span>",
"    &nbsp;&mdash;&nbsp;These members of the subfamily Vespinae are considered to be the most common source of stings in temperate regions due to their abundance and colony aggressiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. There are considered to be 20 species of yellow jackets and hornets in the United States and Canada, although the group's taxonomy has been historically unstable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A few species have a unique appearance and can be readily identified (",
"    <a class=\"graphic graphic_algorithm graphicRef80397 \" href=\"UTD.htm?24/14/24815\">",
"     algorithm 1",
"    </a>",
"    ). The remaining species have similar patterns of bright yellow and black and the patterns are often variable within a species. Thus, a specialist may be required to positively identify them.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genus Vespa &mdash; This genus comprises the true hornets, most of which are found in eastern Asia. A single, introduced species is found in the United States: Vespa crabro, commonly called the European hornet (",
"      <a class=\"graphic graphic_picture graphicRef81978 \" href=\"UTD.htm?35/20/36167\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"       table 1",
"      </a>",
"      ). It is a large brown and yellow wasp that typically nests in tree cavities, attics, or outbuildings. It is not a common source of stings due to its relative scarcity, non-scavenging behavior, and high visibility (making surprise encounters unlikely) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genus Dolichovespula &mdash; This genus of yellow jackets is distinguished by their familiar, grey aerial nests constructed on buildings or in vegetation (",
"      <a class=\"graphic graphic_picture graphicRef66182 \" href=\"UTD.htm?28/5/28760\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66947 \" href=\"UTD.htm?14/24/14728\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"       table 1",
"      </a>",
"      ). They are often colloquially called \"hornets\" in the United States, probably because one common, atypically large species superficially resembles the European hornet [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/3\">",
"       3",
"      </a>",
"      ]. This distinctive black and white wasp, Dolichovespula maculata, even has the accepted common name of \"bald-faced hornet\" (sometimes incorrectly referred to as a \"white-faced hornet\") (",
"      <a class=\"graphic graphic_picture graphicRef66754 \" href=\"UTD.htm?22/32/23046\">",
"       picture 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/2\">",
"       2",
"      </a>",
"      ]. A second abundant species, D. arenaria, is the size and color of most other yellow jackets, and has the common name of aerial yellow jacket [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/2\">",
"       2",
"      </a>",
"      ]. It is also referred to as the \"yellow hornet\", a confusing misnomer that should be discontinued [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/2,24\">",
"       2,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genus Vespula &mdash; This genus of yellow jackets builds nests in cavities, either subterranean or in protected structural locations such as wall voids and attics (",
"      <a class=\"graphic graphic_picture graphicRef80411 \" href=\"UTD.htm?0/33/535\">",
"       picture 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"       table 1",
"      </a>",
"      ). One group of six species is particularly important in the United States and Canada, due to their large colony size (potentially about 5000 living workers at colony maturity), long colony life (sometimes persisting into early winter), and propensity for scavenging a wide range of human foods. These species are V. vulgaris (common yellow jacket), V. maculifrons (Eastern yellow jacket), V. pensylvanica (Western yellow jacket), V. squamosa (Southern yellow jacket), V. germanica (German yellow jacket), and V. flavopilosa (",
"      <a class=\"graphic graphic_picture graphicRef62180 \" href=\"UTD.htm?26/38/27236\">",
"       picture 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef80671 \" href=\"UTD.htm?14/12/14533\">",
"       picture 11",
"      </a>",
"      ). Colonies of these species typically have a single queen and last for one season only, as with all temperate social wasps. However, in areas with mild winters, including the southeastern states, California, and Hawaii, multiple queens may coexist in the same nest and produce enormous perennial colonies with a high potential for mass stinging [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/1,25\">",
"       1,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical studies and field observations have shown that both the Eastern yellow jacket and V. flavopilosa often anchor their stings firmly in human skin (",
"    <a class=\"graphic graphic_picture graphicRef74030 \" href=\"UTD.htm?37/18/38178\">",
"     picture 12",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/21,26-28\">",
"     21,26-28",
"    </a>",
"    ]. The wasps cannot pull away from (ie, autotomize) their sting. However, the embedded sting apparatus is readily torn from the wasp's abdomen if the insect is forcibly removed by the victim. This mechanism of sting loss by traumatic evisceration is functionally similar to the true autotomy of honey bees since it is associated with the release of alarm pheromone and prolonged injection of venom [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/21,26-28\">",
"     21,26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Paper wasps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paper wasps (members of the subfamily Polistinae) are another common source of human stings in temperate areas. There are 24 species of paper wasps in the United States and Canada. Identification of these species is particularly difficult for the nonspecialist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/23,29\">",
"     23,29",
"    </a>",
"    ]. Paper wasps are more slender and elongated than yellow jackets (",
"    <a class=\"graphic graphic_figure graphicRef76529 \" href=\"UTD.htm?8/44/8900\">",
"     figure 1",
"    </a>",
"    ). They construct distinctive nests of only one comb without any protective covering (",
"    <a class=\"graphic graphic_picture graphicRef77793 \" href=\"UTD.htm?33/34/34343\">",
"     picture 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"     table 1",
"    </a>",
"    ). The colonies are typically small, with no more than a few dozen workers. However, their nests can be abundant around human habitations. A recently introduced species, P. dominula (often incorrectly cited as dominulus), is especially pestiferous since it nests in both exposed and protected locations, including readily disturbed structural cavities such as hollow fencing, light fixtures, and playground equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/23,30-32\">",
"     23,30-32",
"    </a>",
"    ]. Its atypically bright yellow and black pattern and relatively small size and compact shape frequently result in it being misidentified as a yellow jacket (",
"    <a class=\"graphic graphic_picture graphicRef64729 \" href=\"UTD.htm?6/15/6391\">",
"     picture 14",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Solitary wasps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several families of wasps, including Vespidae, contain solitary species. Most are innocuous, although, as with bees, a few occasionally come to the attention of clinicians either because of unusual stinging incidents or patient concerns due to their appearance.",
"   </p>",
"   <p>",
"    Cicada killers (Sphecius spp, Crabronidae, formerly treated as part of Sphecidae) are enormous wasps that prey on annual cicadas. They nest in the ground, often excavating conspicuous mounds of earth in the process. Numerous females will sometimes dig their burrows in the same vicinity, resulting in large numbers of males (",
"    <a class=\"graphic graphic_picture graphicRef70363 \" href=\"UTD.htm?30/20/31047\">",
"     picture 15",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66768 \" href=\"UTD.htm?7/63/8189\">",
"     table 1",
"    </a>",
"    ) flying back and forth in the area.",
"   </p>",
"   <p>",
"    Mud daubers (Crabronidae and Sphecidae) frequently build their earthen nests in protected areas on structures (",
"    <a class=\"graphic graphic_picture graphicRef60776 \" href=\"UTD.htm?40/27/41399\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Velvet ants are the wingless, ant-like females of wasp species in the family Mutillidae [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9271/abstract/6,33\">",
"     6,33",
"    </a>",
"    ]. They are typically covered in bright red and black hair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The great majority of bee and wasp species are solitary or primitively social, and will not use their stings to defend their nests. They are therefore harmless to humans unless accidentally pressed against the skin. Included in this group are such familiar forms as carpenter bees, mining (or digger) bees, cicada killer wasps, and mud dauber wasps. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Solitary bees'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Solitary wasps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In temperate areas, almost all stings from bees and wasps are from three highly social groups: honey bees, vespine wasps (yellow jackets and hornets) and polistine wasps (paper wasps). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Social bees'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Social wasps'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Africanized honey bees are now found throughout much of the southern United States. This insect constitutes the most dangerous stinging threat to humans in areas where it occurs, due to the extreme sensitivity of their colonies to disturbance and their typically massive and prolonged attacks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Honey bees'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/1\">",
"      Greene A, Breisch NL. Avoidance of bee and wasp stings: an entomological perspective. Curr Opin Allergy Clin Immunol 2005; 5:337.",
"     </a>",
"    </li>",
"    <li>",
"     Entomological Society of America. Common names of insects and related organisms. www.entsoc.org/pubs/common_names/index.htm (Accessed on July 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/3\">",
"      Greene A, Caron DM. Entomological etymology: the common names of social wasps. Bull Entomol Soc Am 1980; 26:126.",
"     </a>",
"    </li>",
"    <li>",
"     Snodgrass RE. The anatomy of the honey bee, USDA Tech Series, 1910. p.18.",
"    </li>",
"    <li>",
"     Akre RD, Reed HC. Vespine defense. In: Defensive mechanisms in social insects, Hermann HR (Ed), Praeger, New York 1984. p.59.",
"    </li>",
"    <li>",
"     O'Neill KM. Solitary wasps: Behavior and natural history, Cornell Univ Press, Ithaca, NY 2001.",
"    </li>",
"    <li>",
"     Michener CD. The bees of the world, Johns Hopkins Univ Press, Baltimore 2007.",
"    </li>",
"    <li>",
"     Winston ML. The biology of the honey bee, Harvard Univ Press, Cambridge, MA 1987.",
"    </li>",
"    <li>",
"     Goulson D. Bumblebees: Their behaviour and ecology, Oxford Univ Press, Oxford, UK 2003.",
"    </li>",
"    <li>",
"     Ruttner F. Biogeography and taxonomy of honeybees, Springer-Verlag, Berlin 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/11\">",
"      Sakagami SF, Akahira Y. Studies on Apis cerana cerana Fabricius. VIII. Two opposing adaptations in the post-stinging behavior of honeybees. Evolution 1960; 14:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/12\">",
"      Poore DM. Sting autotomy. Am Bee J 1974; 114:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/13\">",
"      Seeley TD, Morse RA. The nest of the honey bee (Apis mellifera L.). Insectes Soc 1976; 23:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/14\">",
"      Seeley TD, Morse RA. Nest site selection by the honey bee, Apis mellifera. Insectes Soc 1978; 25:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/15\">",
"      Winston ML. The biology and management of Africanized honey bees. Ann Rev Entomol 1992; 37:173.",
"     </a>",
"    </li>",
"    <li>",
"     Winston ML. Killer bees: The Africanized honey bee in the Americas., Harvard Univ Press, Cambridge, MA 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/17\">",
"      Sherman RA. What physicians should know about Africanized honeybees. West J Med 1995; 163:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/18\">",
"      Breed MD, Guzm&aacute;n-Novoa E, Hunt GJ. Defensive behavior of honey bees: organization, genetics, and comparisons with other bees. Annu Rev Entomol 2004; 49:271.",
"     </a>",
"    </li>",
"    <li>",
"     Akre RD, Greene A, MacDonald JF, et al. The yellowjackets of America north of Mexico, A Agric Handbook, 552 1981.",
"    </li>",
"    <li>",
"     The social biology of wasps, Ross KG, Matthews RW (Eds), Cornell Univ Press, Ithaca, NY 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/21\">",
"      Greene A, Breisch NL, Golden DBK, et al. Sting embedment and avulsion in yellowjackets (Hymenoptera: Vespidae): A functional equivalent to autotomy. Am Entomol 2012; 58:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/22\">",
"      Carpenter JM, Kojima J. Checklist of the species in the subfamily Vespinae (Insecta: Hymenoptera: Vespidae). Nat Hist Bull Ibaraki Univ 1997; 1:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/23\">",
"      Buck M, Marshall SA, Cheung DKB. Identification atlas of the Vespidae (Hymenoptera, Aculeata) of the northeastern Nearctic region. Can J Arthropod Ident 2008; :5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/24\">",
"      Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157.",
"     </a>",
"    </li>",
"    <li>",
"     Greene A. Dolichovespula and Vespula. In: The social biology of wasps, Ross KG, Matthews RW (Eds), nell Univ Press, Ithaca, NY 1991. p.263.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/26\">",
"      Greene A, Breisch NL, Golden DBK, et al. The sting that stays: autotomy in two common yellowjacket species. J Allergy Clin Immunol 1989; 83:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/27\">",
"      Mulfinger L, Yunginger J, Styer W, et al. Sting morphology and frequency of sting autotomy among medically important vespids (Hymenoptera: Vespidae) and the honey bee (Hymenoptera: Apidae). J Med Entomol 1992; 29:325.",
"     </a>",
"    </li>",
"    <li>",
"     Vail KM, Skinner JA. Yellowjacket wasps in Tennessee. Univ Tenn SP 2000; 341M.",
"    </li>",
"    <li>",
"     Carpenter JM. Distributional checklist of species of the genus Polistes (Hymenoptera: Vespidae; Polistinae, Polistini). Amer Mus Nov 1996; 3188.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/30\">",
"      Cervo R, Zacchi F, Turillazzi S. Polistes dominulus (Hymenoptera, Vespidae) invading North America: some hypotheses for its rapid spread. Insectes Soc 2000; 47:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/31\">",
"      Silagi SA, Gamboa GJ, Klein CR, Noble MA. Behavioral differences between two recently sympatric paper wasps, the native Polistes fuscatus and the invasive Polistes dominulus. Great Lakes Entomol 2003; 36:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9271/abstract/32\">",
"      Gamboa GJ, Noble MA, Thom MC, et al. The comparative biology of two sympatric paper wasps in Michigan, the native Polistes fuscatus and the invasive Polistes dominulus (Hymenoptera, Vespidae). Insectes Soc 2004; 51:153.",
"     </a>",
"    </li>",
"    <li>",
"     Pulawski W. Family group names and classification as of May 22, 2009. file://research.calacademy.org/research/entomology/entomology_resources/Hymenoptera/sphecidae/Family_group_names_and_classification.pdf (Accessed on July 13, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4093 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9271=[""].join("\n");
var outline_f9_3_9271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIOLOGY AND IDENTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Social bees",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Bumble bees",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Honey bees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Solitary bees",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Social wasps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Yellow jackets and hornets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Paper wasps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Solitary wasps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4093|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/14/24815\" title=\"algorithm 1\">",
"      Hymenoptera taxonomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4093|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/44/8900\" title=\"figure 1\">",
"      Polistes species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4093|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/61/7125\" title=\"picture 1\">",
"      Bumble bee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/3/34869\" title=\"picture 2\">",
"      Honey bee 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/5/15443\" title=\"picture 3\">",
"      Sweat bee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/25/22931\" title=\"picture 4\">",
"      Carpenter bee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/20/36167\" title=\"picture 5\">",
"      European hornets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/5/28760\" title=\"picture 6\">",
"      Aerial yellowjacket nest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/24/14728\" title=\"picture 7\">",
"      Dolichovespula nest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/32/23046\" title=\"picture 8\">",
"      Bald-faced hornets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/33/535\" title=\"picture 9\">",
"      Vespula nest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/38/27236\" title=\"picture 10\">",
"      Vespula species",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/12/14533\" title=\"picture 11\">",
"      Vespula worker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/18/38178\" title=\"picture 12\">",
"      Vespula sting anchoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/34/34343\" title=\"picture 13\">",
"      Paper wasp nest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/15/6391\" title=\"picture 14\">",
"      Polistes dominula worker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/20/31047\" title=\"picture 15\">",
"      Cicada killer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/27/41399\" title=\"picture 16\">",
"      Mud dauber",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4093|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/63/8189\" title=\"table 1\">",
"      Hymenoptera characteristics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/1/12313?source=related_link\">",
"      Bee, yellow jacket, wasp, and other Hymenoptera stings: Reaction types and acute management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/22/6502?source=related_link\">",
"      Bees, yellow jackets, hornets, and wasps: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14824?source=related_link\">",
"      Diagnosis of Hymenoptera venom allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7752?source=related_link\">",
"      Entomology and control of imported fire ants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16936?source=related_link\">",
"      Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7994?source=related_link\">",
"      Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9272="Retroperitoneal lymph node dissection in testicular germ cell tumors";
var content_f9_3_9272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retroperitoneal lymph node dissection in testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9272/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9272/contributors\">",
"     Graeme S Steele, MBBCh, FCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9272/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9272/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9272/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9272/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/3/9272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment advances over the past two decades have made testicular cancers, 95 percent of which are germ cell tumors (GCTs), one of the most curable solid tumors. Thirty years ago, testis cancer accounted for 11 percent of all cancer deaths in men between the ages of 25 to 34, and the five-year survival rate was 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/1\">",
"     1",
"    </a>",
"    ]. About 350 deaths from testicular cancer occur in the United States per year from testicular cancer and five-year survival rates are over 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These advances are related to a better understanding of the natural history of testicular tumors, improved staging and surgical techniques, and the introduction of effective platinum-based combination chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/1\">",
"     1",
"    </a>",
"    ]. The consistently high cure rates in early stage disease have shifted the focus toward reducing treatment-related effects on reproductive function, and the pulmonary, neural, and renal toxicity associated with chemotherapy.",
"   </p>",
"   <p>",
"    Retroperitoneal lymph node dissection (RPLND) has been used, both as a component of therapy in men with early stage GCTs and for the evaluation and treatment of residual masses following systemic chemotherapy for more advanced disease. The indications for RPLND are constantly under review in an attempt to avoid unnecessary surgery and reduce the morbidity of therapy.",
"   </p>",
"   <p>",
"    The techniques and role of RPLND in men with testicular cancer will be reviewed here. Other aspects of the management of men with testicular cancer are discussed in the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOLOGIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following radical inguinal orchiectomy for a testicular tumor, the histologic classification has a major role in clinical decisions regarding the need for further therapy. GCTs, which arise from germ cell elements within the seminiferous tubules, account for 90 to 95 percent of all testicular tumors (",
"    <a class=\"graphic graphic_table graphicRef81626 \" href=\"UTD.htm?43/42/44715\">",
"     table 1",
"    </a>",
"    ). About 50 percent of these are seminomas, and the remainder are referred to as nonseminomatous germ cell tumors (NSGCTs). Non-GCTs include neoplasms arising from gonadal stroma and mesenchymal structures in addition to other miscellaneous lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"     \"Anatomy and pathology of testicular tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Metastatic potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with NSGCT present with clinical stage I disease (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, between 30 and 50 percent have clinically occult metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/4\">",
"     4",
"    </a>",
"    ]. A number of histologic factors can help to predict the likelihood of recurrent disease in men with clinical stage I NSGCT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vascular or lymphatic invasion",
"     </li>",
"     <li>",
"      Primary tumor (T) stage T2 - T3",
"     </li>",
"     <li>",
"      Embryonal carcinoma &gt;40 percent of total tumor volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, in one study that included 259 men with stage I NSGCT, the two-year relapse rate for those in the high-risk subgroup (all three of these risk factors present) was 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment decisions can be individualized based upon these risk factors. Following orchiectomy, surveillance rather than an RPLND can be recommended for men who have a low risk of recurrence. In contrast, chemotherapy or RPLND rather than surveillance may be indicated for those who with at increased risk of occult metastatic disease.",
"   </p>",
"   <p>",
"    However, histologic distinctions between high- and low-risk disease are not accurate enough in their predictive capability to dictate treatment planning in men with clinical stage I NSGCT. More than one-half of men who eventually relapse had low-risk disease at their initial presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LYMPHATIC DRAINAGE AND PATTERNS OF METASTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles underlying the surgical treatment of testicular GCT are based upon the step-wise predictable metastatic pattern of these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/9\">",
"     9",
"    </a>",
"    ]. Choriocarcinoma is an exception to this pattern of spread and tends to metastasize hematogenously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Retroperitoneal lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spermatic cord contains lymphatic channels that ascend into the retroperitoneal lymph node chain. The interaortocaval nodes, at the level of the second lumbar vertebral body, are the first echelon of lymph nodes draining the right testis. The first lymph nodes draining the left testis are located in the paraaortic region in an area bounded by the renal vein superiorly, the aorta medially, the ureter laterally and the origin of the inferior mesenteric artery (IMA) inferiorly. Secondary lymphatic spread may occur in a retrograde fashion to the common external and inguinal nodes, or cephalad via the cysterna chyli, thoracic duct and supraclavicular nodes.",
"   </p>",
"   <p>",
"    In a review of 104 consecutive cases of stage II NSGCT, a number of important observations were made confirming the predictability of lymphatic spread in testicular cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/9\">",
"     9",
"    </a>",
"    ]. Although retroperitoneal lymph node spread above the renal hilum was rare in stage IIA disease, suprahilar spread was not uncommon in stage IIB disease (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contralateral node involvement was not common in patients with early stage disease, but was more likely in patients with right-sided tumors, because of lymphatic drainage from right to left. These observations have important implications for the surgical management of testis cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pelvic and inguinal lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatics of the epididymis drain into the external iliac nodes. As a result, positive pelvic nodes may result from locally advanced disease with epididymal involvement. Inguinal node metastases may result by retrograde spread from extensive retroperitoneal nodes, scrotal invasion, or a scrotal rather than inguinal orchiectomy. Scrotal violation during orchiectomy for testis cancer has been avoided in the past because of concern for poorer outcome. However, recent data have challenged this view [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=see_link\">",
"     \"Radical inguinal orchiectomy for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Distant spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 5 percent of men develop metastatic disease at distant sites following a node-negative RPLND [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/12\">",
"     12",
"    </a>",
"    ]. This is probably due to the testicular lymphatics bypassing the retroperitoneal lymph nodes and communicating directly with the thoracic duct. Distant spread of testis cancer occurs most commonly to the lungs, with subsequent spread to the liver, viscera, and brain; bone metastases are generally a late and rare complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of men with suspected testicular cancer includes scrotal ultrasound followed by radiographic staging evaluation, measurement of serum tumor markers, and, in early stage disease, radical inguinal orchiectomy. Treatment decisions depend upon accurate identification of the stage or extent of disease spread (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One limitation of staging the retroperitoneum by CT scanning is a high false-negative rate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/13\">",
"     13",
"    </a>",
"    ]. Occult micrometastases are responsible for most of these false negatives, as evidenced by a retroperitoneal relapse rate of 20 to 25 percent in men with clinical stage I disease who defer RPLND [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, following radical inguinal orchiectomy and radiographic staging of the retroperitoneum, patients with apparently low-stage NSGCT (T1-3 N0-2 M0) are potential candidates for a surgical staging RPLND. RPLND is the only reliable method to identify nodal micrometastases and is the gold standard for providing accurate pathologic staging of the retroperitoneum.",
"   </p>",
"   <p>",
"    For men with high-volume stage II or III disease, primary chemotherapy is the treatment of choice. In this subset of patients, RPLND is reserved for patients with residual post chemotherapy disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgical management of advanced testicular germ cell tumors\", section on 'RPLND after chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The conventional approach to evaluation and treatment of the retroperitoneum in patients with early stage NSGCT has been the modified bilateral RPLND. Newer surgical techniques can provide accurate pathological staging and therapeutic benefit, while minimizing adverse effects on sexual function. As a result, the classic bilateral RPLND has been largely replaced with template dissections for both right- and left-sided disease, resulting in preservation of emission and antegrade ejaculation in the majority of men. Emerging laparoscopic techniques for RPLND are also associated with reduced morbidity when compared to the classic full RPLND and may have an expanded future role (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Surgical principles'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A full understanding of sexual dysfunction following RPLND requires a brief review of the neuroanatomic basis of ejaculation in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NEUROANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antegrade propulsion of semen through the urethra requires coordination of three separate events: closure of the bladder neck, seminal emission, and ejaculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Emission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emission is the movement of semen into the posterior urethra immediately prior to ejaculation. Emission is mediated by sympathetic nerves from spinal segments T12 to L3 and affected by contractions of the vas deferens, prostate and seminal vesicles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ejaculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ejaculation is the passage of semen distally through the urethra; it results from tightening of the closed bladder neck (sympathetic reflex), relaxation of the external sphincter (parasympathetic reflex), and contraction of the bulbocavernosus muscle (somatic innervation via the pudendal nerve). Thus, ejaculation is mediated by combined autonomic and somatic innervation originating at the sacral and lumbar spinal cord levels.",
"   </p>",
"   <p>",
"    The sympathetic nerves responsible for emission and bladder neck closure during ejaculation leave the spinal cord with the ventral roots of the twelfth thoracic (T12) to the third lumbar (L3) spinal nerves. These nerves pass to the paravertebral sympathetic ganglion chain, located beneath the medial edge of the vena cava on the right, and the aorta on the left; the sympathetic ganglion chain lies in the gutter between the vertebral bodies and the psoas muscle. In the mid-retroperitoneum, after leaving the sympathetic trunk, the fibers converge toward midline and form the hypogastric plexus, situated in front of the body of fifth lumbar vertebra and the bifurcation of the abdominal aorta, and behind the left common iliac vein. From the superior hypogastric plexus, the right and left hypogastric nerves pass down into the pelvic plexuses, which are situated on either side of the rectum, seminal vesicles, bladder and prostate.",
"   </p>",
"   <p>",
"    In patients undergoing RPLND, preserving emission and ejaculation requires avoidance of injury to sympathetic chains, their visceral branches, the superior hypogastric plexus, and the postganglionic sympathetic fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/17\">",
"     17",
"    </a>",
"    ]. This principle underlies both the template RPLND, in which the dissection is limited to above the takeoff of the IMA on the contralateral side (thus avoiding the contralateral sympathetic fibers and the hypogastric plexus), and nerve sparing dissections in which lumbar postganglionic nerves are prospectively identified and preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Both nerve dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] and nerve-avoiding RPLND templates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/21-23\">",
"     21-23",
"    </a>",
"    ] are associated with preservation of ejaculation in 80 percent or more of men [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Surgical principles'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STAGE I AND II GCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic options following radical inguinal orchiectomy for stage I and II NSGCTs include RPLND, surveillance, or adjuvant chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link&amp;anchor=H647555688#H647555688\">",
"     \"Overview of the treatment of testicular germ cell tumors\", section on 'Non-seminomatous germ cell tumor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For men with low-risk clinical stage I NSGCT, long-term survival is identical with all three of these approaches, just as it is in patients with low stage seminoma who are willing and able to comply fully with an active surveillance regimen; we suggest surveillance following orchiectomy as long as they are willing and able to comply. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For those who decline surveillance or are not good candidates for surveillance, we suggest a retroperitoneal lymph node dissection. However, one or two cycles of adjuvant platinum-based chemotherapy is a reasonable alternative. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Rationale for RPLND'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For men with high-risk clinical stage I NSGCTs, we suggest a retroperitoneal lymph node dissection. However, adjuvant chemotherapy with one or two cycles of platinum-based chemotherapy is a reasonable alternative. Given their risk, we do not suggest surveillance as an option. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Rationale for RPLND'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Adjuvant chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The data on these modalities of treatment and for surveillance are reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Rationale for RPLND",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several advantages to the performance of RPLND rather than surveillance or adjuvant chemotherapy in low stage NSGCT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RPLND provides accurate pathologic staging, permitting the selection of those who may benefit from postoperative chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"       \"Management of stage I nonseminomatous germ cell tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"       \"Management of stage II nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since the incidence of retroperitoneal relapse is less than one percent in those with pathologically confirmed stage I disease, patient follow-up after RPLND involves only tumor markers and chest x-rays [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/25\">",
"       25",
"      </a>",
"      ]. Relapse in any site is rare and generally curable with chemotherapy. In contrast, surveillance protocols entail more radiographic imaging; relapse, which occurs in 25 to 30 percent of cases, entails chemotherapy for salvage.",
"     </li>",
"     <li>",
"      RPLND in experienced hands is associated with low short- and long-term morbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Following therapy for testicular cancer, the chance of future successful pregnancies may be higher for men who have a nerve-sparing RPLND [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/27\">",
"       27",
"      </a>",
"      ]. A possible explanation of this observation is that men who are managed with surveillance more frequently require chemotherapy for relapse, which may reduce their long-term fertility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance is appropriate for patients with clinical stage I disease, who are at low risk for relapse and are motivated to rigidly adhere to a surveillance protocol. These patients must fully understand the risks of failure to comply with the follow-up schedule. Retroperitoneal relapse occurs in about 25 to 30 percent of men with clinical stage I disease who are undergoing surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link&amp;anchor=H900673895#H900673895\">",
"     \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy is an alternative to RPLND or surveillance in men with clinical stage I testicular GCTs, and following RPLND in patients with resected stage II disease. A large randomized clinical trial and several case series indicate that adjuvant chemotherapy results in a long-term cure rate similar to that with RPLND. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"     \"Management of stage I nonseminomatous germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"     \"Management of stage II nonseminomatous germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SURGICAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific type of RPLND performed is dependent upon the clinical situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Role of RPLND-I",
"    </span>",
"    &nbsp;&mdash;&nbsp;An RPLND-I is typically performed in men with NSGCT who have normal serum tumor markers and no radiographic features of retroperitoneal involvement, but who have at least one risk factor for micrometastases in retroperitoneal lymph nodes (vascular invasion, embryonal carcinoma volume greater than 40 percent, T2 or T3 stage, (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    )). The absence of retroperitoneal lymph node involvement must be histologically confirmed at surgery.",
"   </p>",
"   <p>",
"    The surgical technique is usually a template or nerve-sparing RPLND. The dissection is complete above the level of the IMA but is limited to the ipsilateral side below the level of the IMA. This approach preserves the sympathetic nerves responsible for emission and antegrade ejaculation in the majority of patients, thus preserving future fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with pathologic stage I NSGCT following RPLND, the recommended post RPLND surveillance schedule includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination, chest X-ray, and serum tumor marker levels every three months for the first year, every six months in the second year, and annually thereafter.",
"     </li>",
"     <li>",
"      CT scan of the abdomen and pelvis annually for three years; this schedule is far less intense than in patients undergoing surveillance following radical orchiectomy alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rate of relapse following RPLND is between 4 and 14 percent; relapse following RPLND almost always occurs outside the retroperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/30\">",
"     30",
"    </a>",
"    ]. Men with elevated serum tumor markers postorchiectomy or clinical stage IIB disease (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 3",
"    </a>",
"    ) have a higher rate of relapse and are generally treated with systemic chemotherapy rather than RPLND. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"     \"Management of stage II nonseminomatous germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with early stage disease who relapse following RPLND are generally salvaged by chemotherapy, and cure rates approach 100 percent. Some clinicians, particularly those practicing in Europe, advocate two cycles of adjuvant chemotherapy as an alternative to RPLND for men with high-risk NSGCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"     \"Management of stage I nonseminomatous germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"     \"Management of stage II nonseminomatous germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Role of RPLND-II",
"    </span>",
"    &nbsp;&mdash;&nbsp;An RPLND-II is appropriate for men with low-volume (stage IIA or IIB) NSGCT who have radiographically evident disease or who are found to have histologically involved retroperitoneal nodes at the time of exploration. The surgical boundaries are wider than in the RPLND-I and include bilateral dissection above the renal arteries and below the IMA. Every attempt is made to preserve both the lumbar sympathetics and the hypogastric plexus, resulting in preservation of normal ejaculation (and future fertility) in the majority of patients undergoing RPLND-II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/21,23,26,29\">",
"     21,23,26,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of relapse in men with stage II testis cancer following an RPLND-II is variable, and depends upon the volume and number of involved retroperitoneal lymph nodes and the use of adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/21,31-33\">",
"     21,31-33",
"    </a>",
"    ]. At least one trial suggests that RPLND followed by two cycles of adjuvant chemotherapy for pathologically positive disease is preferable to four cycles of chemotherapy without RPLND in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/34\">",
"     34",
"    </a>",
"    ]. Others suggest that RPLND alone is appropriate for men with stage IIA disease, with chemotherapy reserved for salvage. As with the RPLND-I, relapse usually occurs outside the retroperitoneum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link&amp;anchor=H110956445#H110956445\">",
"     \"Management of stage II nonseminomatous germ cell tumors\", section on 'Clinical stage II NSGCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Therapeutic RPLND",
"    </span>",
"    &nbsp;&mdash;&nbsp;A therapeutic RPLND (termed an RPLND-III) may be considered for men with either seminoma or NSGCT who have either recurrent retroperitoneal disease, or a residual mass following chemotherapy. The surgical technique involves initial resection of the mass by separating it anterior to the great vessels and ureters. Once the mass has been resected, a standard full bilateral RPLND is performed.",
"   </p>",
"   <p>",
"    The indications for therapeutic RPLND and the implications of various findings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgical management of advanced testicular germ cell tumors\", section on 'RPLND after chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laparoscopic RPLND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic RPLND is an emerging technique that may reduce morbidity compared to the classic full RPLND [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/35\">",
"     35",
"    </a>",
"    ]. Cancer control rates appear to be similar, although there are no randomized trials comparing the two procedures. Several observational series have demonstrated the feasibility of this approach and reported long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the series with the largest series, 87 with stage I GCTs underwent a laparoscopic RPLND for pathologic staging of the retroperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9272/abstract/39\">",
"     39",
"    </a>",
"    ]. Median follow-up for the entire series was 84 months. The 21 patients with positive lymph nodes received two cycles of adjuvant chemotherapy, and all 21 were relapse-free. Among the 66 men with negative lymph nodes, six relapses were observed including one at the port site, all of which were successfully managed. Complications were seen in nine percent of cases.",
"   </p>",
"   <p>",
"    Although laparoscopic RPLND is feasible, this procedure is basically an extension of staging and is",
"    <strong>",
"     not",
"    </strong>",
"    therapeutic. Any man who is found to have positive nodes on laparoscopic RPLND receives two cycles of chemotherapy, while those who undergo open RPLND and are found to have a limited volume of disease are typically followed without chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"     \"Management of stage II nonseminomatous germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term studies of patients who undergo laparoscopic RPLND for low volume stage II disease and are followed without chemotherapy will be necessary to prove the therapeutic equivalence of laparoscopic and open RPLND. The role of laparoscopic RPLND in more advanced stage disease is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with clinical stage I nonseminomatous germ cell tumors (GCTs) and normal serum tumor markers, retroperitoneal lymph node dissection (RPLND), surveillance or an abbreviated course of adjuvant chemotherapy are all options in appropriately selected patients and can be expected to result in cure in more than 98 percent of patients. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Stage I and II GCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with low-risk clinical stage I NSGCT who are willing and able to comply fully with an active surveillance regimen, we suggest surveillance following orchiectomy as long as they are willing and able to comply (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For those who decline surveillance or are not good candidates for surveillance, we suggest a retroperitoneal lymph node dissection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, one or two cycles of adjuvant platinum-based chemotherapy is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Stage I and II GCT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link&amp;anchor=H8532060#H8532060\">",
"       \"Management of stage I nonseminomatous germ cell tumors\", section on 'Retroperitoneal lymph node dissection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with high-risk clinical stage I NSGCTs, we suggest a retroperitoneal lymph node dissection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, adjuvant chemotherapy with one or two cycles of platinum-based chemotherapy is a reasonable alternative (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Given their risk, we do not suggest surveillance as an option. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Stage I and II GCT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link&amp;anchor=H8532060#H8532060\">",
"       \"Management of stage I nonseminomatous germ cell tumors\", section on 'Retroperitoneal lymph node dissection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with clinical stage II NSGCTs and normal serum tumor markers, RPLND or a full course of chemotherapy for disseminated disease can be used, although RPLND is generally preferred for patients with early clinical stage II while chemotherapy is generally preferred for more those with advanced clinical stage II. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Stage I and II GCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men with clinical stage II NSGCT who are thought to have a low probability of relapse following surgery, we suggest RPLND rather than primary chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If tumor involvement is confirmed at surgery, patients are then managed according to their pathologic stage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"       \"Management of stage II nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with clinical stage II NSGCT who are considered to be at increased risk for recurrence, we suggest primary chemotherapy rather than RPLND (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"       \"Management of stage II nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic RPLND (RPLND-III) is used for men who have residual masses following chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H5#H5\">",
"       \"Surgical management of advanced testicular germ cell tumors\", section on 'RPLND after chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      RPLND should be considered as an option only at institutions with a urologist with extensive experience in this procedure (ie, performing at least 24 RPLNDs per year).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/1\">",
"      Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute, Bethesda, MD, 2004 file://seer.cancer.gov/csr/1975_2007/index.html (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/3\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/4\">",
"      Levin HS. Prognostic features of primary and metastatic testis germ-cell tumors. Urol Clin North Am 1993; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/5\">",
"      Leibovitch I, Foster RS, Kopecky KK, et al. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 1998; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/6\">",
"      Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998; 83:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/7\">",
"      Pohar KS, Rabbani F, Bosl GJ, et al. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol 2003; 170:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/8\">",
"      Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987; 2:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/9\">",
"      Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982; 128:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/10\">",
"      Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995; 153:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/11\">",
"      Aki FT, Bilen CY, Tekin MI, Ozen H. Is scrotal violation per se a risk factor for local relapse and metastases in stage I nonseminomatous testicular cancer? Urology 2000; 56:459.",
"     </a>",
"    </li>",
"    <li>",
"     Whitemore WF Jr. Germinal tumors of the testis. In: Proceedings of the Swedish National Cancer Conference, JB Lipincott, Philadelphia 1973. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/13\">",
"      Richie JP, Garnick MB, Finberg H. Computerized tomography: how accurate for abdominal staging of testis tumors? J Urol 1982; 127:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/14\">",
"      Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/15\">",
"      Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995; 13:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/16\">",
"      Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995; 154:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/17\">",
"      Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 1982; 127:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/18\">",
"      Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 1990; 144:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/19\">",
"      Donohue JP, Foster RS, Rowland RG, et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 1990; 144:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/20\">",
"      Jewett MA. Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 1990; 17:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/21\">",
"      Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 1993; 71:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/22\">",
"      Jacobsen KD, Ous S, Waehre H, et al. Ejaculation in testicular cancer patients after post-chemotherapy retroperitoneal lymph node dissection. Br J Cancer 1999; 80:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/23\">",
"      Bell CR, Sibley GN. A 7-year audit in a single centre of the results of the modified template retroperitoneal lymph node dissection for testicular teratoma. BJU Int 1999; 84:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/24\">",
"      Pettus JA, Carver BS, Masterson T, et al. Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology 2009; 73:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/25\">",
"      Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003; 21:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/26\">",
"      Baniel J, Foster RS, Rowland RG, et al. Complications of primary retroperitoneal lymph node dissection. J Urol 1994; 152:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/27\">",
"      Herr HW, Bar-Chama N, O'Sullivan M, Sogani PC. Paternity in men with stage I testis tumors on surveillance. J Clin Oncol 1998; 16:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/28\">",
"      Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 2003; 169:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/29\">",
"      Bryd&oslash;y M, Foss&aring; SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/30\">",
"      Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. J Urol 1985; 134:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/31\">",
"      Vogelzang NJ, Fraley EE, Lange PH, et al. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1983; 1:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/32\">",
"      Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991; 9:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/33\">",
"      Pizzocaro G, Piva L, Salvioni R, et al. Adjuvant chemotherapy in resected stage-II nonseminomatous germ cell tumors of testis. In which cases is it necessary? Eur Urol 1984; 10:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/34\">",
"      Weissbach L, Bussar-Maatz R, Flechtner H, et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000; 37:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/35\">",
"      Carver BS, Sheinfeld J. The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nat Clin Pract Urol 2005; 2:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/36\">",
"      Janetschek G, Hobisch A, Peschel R, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 2000; 163:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/37\">",
"      Bhayani SB, Ong A, Oh WK, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003; 62:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/38\">",
"      Rassweiler JJ, Frede T, Lenz E, et al. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000; 37:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9272/abstract/39\">",
"      Cresswell J, Scheitlin W, Gozen A, et al. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience. BJU Int 2008; 102:844.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2992 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9272=[""].join("\n");
var outline_f9_3_9272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOLOGIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Metastatic potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LYMPHATIC DRAINAGE AND PATTERNS OF METASTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Retroperitoneal lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pelvic and inguinal lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Distant spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NEUROANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Emission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ejaculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STAGE I AND II GCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Rationale for RPLND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SURGICAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Role of RPLND-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Role of RPLND-II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Therapeutic RPLND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laparoscopic RPLND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/42/44715\" title=\"table 1\">",
"      Testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 2\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/34/21037\" title=\"table 3\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=related_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=related_link\">",
"      Management of stage I nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=related_link\">",
"      Management of stage II nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=related_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9273="Indications for parathyroidectomy in end-stage renal disease";
var content_f9_3_9273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for parathyroidectomy in end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9273/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9273/contributors\">",
"     Michael Berkoben, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9273/contributors\">",
"     Robert E Cronin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9273/contributors\">",
"     L Darryl Quarles, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9273/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9273/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9273/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/3/9273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of parathyroidectomy in patients with secondary hyperparathyroidism due to renal failure decreased significantly from 1990 to the late 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/1\">",
"     1",
"    </a>",
"    ]. This has been attributed to an increased utilization of medical measures that can suppress parathyroid hormone (PTH) secretion, the most important being control of hyperphosphatemia and calcitriol supplementation, which also raises the serum calcium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some data suggest that the incidence of parathyroidectomy in the United States may have actually risen over the last few years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/2\">",
"     2",
"    </a>",
"    ]. Using Medicare billing claims over the last decade, one study reported that the annual incidence first declined from 1994 to 1998 (12.5 and 6.8 per 1000 patient years, respectively) and then increased progressively to 11.8 per 1000 patient years in the year 2002. The reasons for this possible increase are unclear.",
"   </p>",
"   <p>",
"    In some geographic areas, the incidence of parathyroidectomy has not significantly changed over time. When evaluated at seven years from the time of initiation of dialysis, the incidence of parathyroidectomy in patients who began renal replacement therapy in an area of Italy between 1990 and 1992 was no different from that observed in patients who started dialysis between 1983 and 1985 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emergence of new therapies, such as calcimimetic agents, may further decrease the need for parathyroidectomy. In a combined analysis of four randomized trials, for example, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    , compared with placebo, markedly lowered the risk of parathyroidectomy (RR of 0.07, 95% CI 0.01-0.55) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF REFRACTORY HYPERPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in care, a subset of patients with end-stage renal disease still have marked elevations in serum parathyroid hormone levels. Data are lacking regarding whether chronic elevations of PTH in asymptomatic patients warrant parathyroidectomy. Nevertheless, surgery is often performed when patients develop refractory hyperparathyroidism (often with serum PTH concentrations above 800",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disorder (called tertiary hyperparathyroidism if hypercalcemia is present) is due to hyperfunctioning parathyroid tissue that does not respond appropriately to physiological regulation or to medical therapy with oral calcium salts and calcitriol. Several interrelated factors are thought to be involved in the pathogenesis of refractory hyperparathyroidism. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delayed",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inadequate therapy",
"     </li>",
"     <li>",
"      Persistent hyperphosphatemia",
"     </li>",
"     <li>",
"      Acquired abnormalities of the parathyroid glands",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acquired abnormalities, which may be the most important, include increases in parathyroid gland mass due to polyclonal parathyroid cell proliferation (diffuse hyperplasia) and monoclonal expansion of adenomatous-like tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When exposed to stimuli such as hypocalcemia, calcitriol deficiency, and hyperphosphatemia, parathyroid cells quickly respond with increased mitotic activity, leading to parathyroid gland hyperplasia. Regression of established hyperplasia occurs slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/7\">",
"     7",
"    </a>",
"    ], perhaps due to a low rate of apoptotic cell death in the parathyroid glands [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/8\">",
"     8",
"    </a>",
"    ]. This may explain why significant hyperplasia is sometimes irreversible. Polyclonal hyperplasia leads to refractory hyperparathyroidism because each cell may have a low amount of nonsuppressible basal PTH secretion. In this setting, persistent hyperparathyroidism results from the summation of the contributions from the markedly increased number of cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, somatic mutations in the proliferating parathyroid cells lead to monoclonal expansion and adenomatous transformation. This transformation promotes the development of refractory hyperparathyroidism because the adenomatous cells do not respond to normal suppressive stimuli such as the serum calcium concentration and calcitriol. The autonomous behavior may be caused by reduced expression of the extracellular calcium-sensing receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/9\">",
"     9",
"    </a>",
"    ] and lower vitamin D receptor density in the adenomatous cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PARATHYROIDECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidance relating to the indications for parathyroidectomy is significantly hampered by the lack of randomized, controlled trials comparing the long-term effects of medical versus surgical therapy of advanced secondary hyperparathyroidism. Parathyroidectomy in end-stage renal disease is primarily performed in symptomatic patients with markedly elevated and nonsuppressible serum PTH values. There is not sufficient evidence to justify parathyroidectomy based upon serum PTH alone in asymptomatic patients.",
"   </p>",
"   <p>",
"    Symptoms are protean and may include those related to hypercalcemia, hyperparathyroid bone and musculoskeletal disease,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calciphylaxis with soft tissue calcifications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"     \"Clinical manifestations of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=see_link\">",
"     \"Calciphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main indications for parathyroidectomy are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe hypercalcemia.",
"     </li>",
"     <li>",
"      Progressive and debilitating hyperparathyroid bone disease as defined by radiographic or histologic evaluation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=see_link\">",
"       \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pruritus that does not respond to medical or dialytic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6937?source=see_link\">",
"       \"Uremic pruritus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Progressive extraskeletal calcification or calciphylaxis that is usually associated with hyperphosphatemia that is refractory to oral phosphate binders. In this setting, PTH-induced release of phosphate from bone contributes to the persistent elevation in the serum phosphate concentration. Parathyroidectomy will tend to minimize further calcification by lowering the serum calcium and phosphate concentrations (",
"      <a class=\"graphic graphic_figure graphicRef72139 \" href=\"UTD.htm?17/35/17982\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Otherwise unexplained symptomatic myopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to appreciate that many of these problems can develop in dialysis patients without significant hyperparathyroidism. Thus, parathyroidectomy should not be performed unless very high PTH levels have been documented. Most dialysis patients undergoing parathyroidectomy have a serum intact PTH concentration above 800",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"   </p>",
"   <p>",
"    In addition to beneficial effects in the above settings, parathyroidectomy also has a positive impact on nutritional status, and humoral and cellular immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There are conflicting data on the blood pressure response after parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been a trend to consider surgical intervention earlier in the course of secondary hyperparathyroidism in patients with end-stage renal disease, particularly if the estimated weight of a parathyroid gland exceeds 500 or 1000 mg (normal 30 to 40 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. This is in part based upon histopathological studies demonstrating that more than 85 percent of glands weighing over 500 mg have nodular hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/15\">",
"     15",
"    </a>",
"    ]. As noted above, nodular parathyroid tissue is less responsive to the usual stimuli that suppress PTH secretion, such as serum calcium and calcitriol, due to a decreased expression of the extracellular calcium-sensing receptor and diminished vitamin D receptor density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In addition, larger glands may be less likely to respond to medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy exists regarding the indications for parathyroidectomy in other clinical settings. As an example, anemia that is resistant to erythropoietin may improve after parathyroidectomy in patients with marked hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/19\">",
"     19",
"    </a>",
"    ]. Possible mechanisms include a direct effect of PTH on erythropoiesis and marrow fibrosis due to significant osteitis fibrosa cystica. However, this type of anemia is also responsive to medical treatment of secondary hyperparathyroidism with intravenous calcitriol. As a result, resistant anemia alone should not be considered an independent indication for surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also uncertain whether patients with persistent but modest elevations of PTH (between 200 and 800",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    after intensive medical therapy with calcitriol should undergo parathyroidectomy. Since there are no controlled studies that evaluate the long-term risks associated with persistent moderate hyperparathyroidism, such patients are usually managed medically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parathyroidectomy is indicated in renal transplant recipients with persistent hyperparathyroidism in association with hypercalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive and otherwise unexplained renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether parathyroidectomy for severe hyperparathyroidism should be performed",
"    <strong>",
"     prior",
"    </strong>",
"    to renal transplantation is controversial as illustrated by the following observations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the biochemical abnormalities typical of the uremic milieu disappear after successful renal transplantation, the hyperparathyroidism appears to resolve in most, but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/21\">",
"       21",
"      </a>",
"      ], cases.",
"     </li>",
"     <li>",
"      Persistent hyperparathyroidism after transplantation may adversely affect renal function.",
"     </li>",
"     <li>",
"      Via unclear mechanisms, there is a risk of abrupt deterioration of renal allograft function after surgical parathyroidectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/22\">",
"       22",
"      </a>",
"      ]. This phenomenon has also been observed in patients with chronic renal failure or end-stage renal disease with residual renal function [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the risk of persistent hyperparathyroidism seems to be too small to justify surgical intervention in all patients with severe secondary hyperparathyroidism on the transplant waiting list, since approximately 96 percent appear to do well. On the other hand, potential problems that may arise if parathyroid overactivity persists have to be given serious consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Aluminum exposure and other bone diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of aluminum exposure and the presence of other forms of renal osteodystrophy (such as",
"    <span class=\"nowrap\">",
"     adynamic/aplastic",
"    </span>",
"    disease) should also be considered when evaluating patients for parathyroidectomy. Both aluminum-associated low turnover bone disease and",
"    <span class=\"nowrap\">",
"     aplastic/adynamic",
"    </span>",
"    bone disease can mimic hyperparathyroidism by causing hypercalcemia, bone pain, and similar radiographic features. Furthermore, it is widely believed that parathyroidectomy can predispose to both aluminum-related osteomalacia and",
"    <span class=\"nowrap\">",
"     adynamic/aplastic",
"    </span>",
"    bone disease, especially if hypoparathyroidism is induced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/25\">",
"     25",
"    </a>",
"    ]. It is therefore recommended that serum PTH values remain above 100",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    after parathyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another potentially serious problem is that parathyroidectomy may lead to exacerbation of aluminum-induced osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Although aluminum accumulation is no longer a major problem, it is still important to exclude markedly excessive aluminum accumulation before proceeding with parathyroidectomy. Preoperative bone biopsy is not recommended for all patients. In particular, bone biopsy is not necessary for those patients with markedly elevated PTH levels who do not have a history of significant aluminum exposure. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, transcortical iliac crest bone biopsy should be performed if there is uncertainty regarding the underlying bone disease or the presence of an aluminum burden. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=see_link\">",
"     \"Bone biopsy and the diagnosis of renal osteodystrophy\"",
"    </a>",
"    .) Parathyroidectomy should be deferred in patients with moderate to marked aluminum deposition until chelation therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    has lowered body aluminum stores. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal parathyroid gland weighs 30 to 40 mg; in comparison, a hyperplastic gland in patients with secondary hyperparathyroidism may weigh as much as two to three grams. Although four glands are typical, there is considerable variability in the number of parathyroid glands. Supernumerary glands are present in as many as 13 percent of subjects, with some patients having six glands or more [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also considerable variability in the location of the parathyroid glands. Thus, identification of all glands often requires careful exploration of the upper mediastinum, thyroid gland, carotid sheaths, and retroesophageal area [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/29\">",
"     29",
"    </a>",
"    ]. If four glands are not identified, persistent or recurrent hyperparathyroidism occurs in as many as 14 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. In addition to identification and removal of four glands, most authors advocate transcervical thymectomy in order to excise any supernumerary glands.",
"   </p>",
"   <p>",
"    Because of these difficulties, some physicians have utilized radionuclide scanning to help detect hyperplastic parathyroid glands. These techniques, particularly technetium-sestamibi scanning, have been extensively studied in patients with primary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=see_link\">",
"     \"Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, little is known concerning their accuracy in patients with secondary hyperparathyroidism due to renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sensitivity of technetium-99m-sestamibi and I-123 subtraction single photon emission computed tomography (SPECT) was assessed in a series of 19 patients with renal failure and secondary hyperparathyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/34\">",
"       34",
"      </a>",
"      ]. Scanning correctly identified 57 of 74 hyperplastic glands found at surgery, resulting in a sensitivity of 77 percent.",
"     </li>",
"     <li>",
"      Another report evaluated preoperative imaging with the parathyroid technetium-99m-sestamibi and I-123 subtraction scintigraphy technique in 11 patients with secondary hyperparathyroidism referred for first parathyroid surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/35\">",
"       35",
"      </a>",
"      ]. Forty-one of 45 glands found at surgery were detected by preoperative scanning (91 percent sensitivity), with no false positive scans. The technique was also able to identify ectopic and supernumerary parathyroid glands.",
"     </li>",
"     <li>",
"      In a study of 21 consecutive patients, the results using the combination of dual phase dual isotope iodine",
"      <span class=\"nowrap\">",
"       123/technetium",
"      </span>",
"      Tc 99m Sestamibi scintigraphy plus high resolution ultrasonography was compared to that found with surgical and histolopathologic findings [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/36\">",
"       36",
"      </a>",
"      ]. The combination of both techniques detected 88 percent of all hyperplastic parathyroid glands (with surgery producing a success rate of 99 percent). Most missed glands with ultrasonography were of low weight, while scintigraphy missed glands located superiorly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It remains to be determined whether or not the preoperative use of such localization techniques in patients with hyperparathyroidism due to renal failure affects outcomes, such as the rate of surgical complications and long-term failures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three surgical procedures have been employed for the treatment of refractory hyperparathyroidism:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Subtotal parathyroidectomy",
"     </li>",
"     <li>",
"      Total parathyroidectomy with autotransplantation",
"     </li>",
"     <li>",
"      Total parathyroidectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Subtotal versus total parathyroidectomy with autotransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized trials comparing these three techniques, but most surgeons perform either subtotal parathyroidectomy or total parathyroidectomy with autoimplantation.",
"   </p>",
"   <p>",
"    Subtotal parathyroidectomy involves excision of all identifiable parathyroid tissue except for 40 to 60 mg of the least hyperplastic gland. Drawbacks to subtotal parathyroidectomy include a substantial risk of persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent disease, which is complicated by greater morbidity if repeat neck exploration is required.",
"   </p>",
"   <p>",
"    For these reasons, some prefer total parathyroidectomy with autotransplantation of small amounts of resected parathyroid tissue into the brachioradialis muscle in the forearm. Other sites for autografting such as the sternocleidomastoid muscle, the subcutaneous tissue of the forearm or presternal area, and abdominal fat have also been successfully used. The main advantage of this approach is the ease of removing recurrent hyperplastic glands from the site of implantation under local anesthesia, without the added morbidity of neck reexploration.",
"   </p>",
"   <p>",
"    There have been numerous reports regarding personal experience with either technique, with each being suggested as the \"procedure of choice\" for the treatment of secondary hyperparathyroidism by different investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Nevertheless, both procedures are extremely successful in controlling the hyperparathyroidism in the short-term; in addition, long-term follow-up also suggests roughly equal proportions of patients with persistent normal PTH levels, recurrent hyperparathyroidism, and permanent hypoparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of reoperation for moderate to severe recurrent hyperparathyroidism is similar with both methods, ranging from 6 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/33,39,40\">",
"     33,39,40",
"    </a>",
"    ]. Recurrent hyperparathyroidism is much more likely to occur with autografting of nodular hyperplastic tissue. In two large studies, for example, the frequency of recurrence was 33 percent with nodular versus only 4 percent with diffuse hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/33,41\">",
"     33,41",
"    </a>",
"    ]. As noted above, nodular areas appear to have a marked reduction in the number of calcitriol receptors, which can contribute to the development of hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Site of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential disadvantage of total parathyroidectomy with autotransplantation is that determining the site of recurrent hyperparathyroidism is often problematic. In one study, the graft was the culprit in only one-half of patients, while hyperplastic tissue found in the neck or mediastinum was responsible for the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several methods have been used to determine the site of recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a venous PTH gradient between the arms suggests that the autograft is responsible for recurrent disease, whereas the lack of a gradient suggests that parathyroid tissue remains in the neck or chest.",
"     </li>",
"     <li>",
"      Another way to determine graft hyperfunction is to temporarily exclude the graft-bearing forearm from the circulation by using the total ischemic blockade technique [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/42\">",
"       42",
"      </a>",
"      ]. This maneuver produces a \"transitory implantectomy\" and reliably identifies patients with graft hyperfunction, by showing a 46 to 87 percent reduction in serum PTH after 10 to 20 minutes of arm ischemia.",
"     </li>",
"     <li>",
"      Detection of residual or ectopic tissue in the neck may be evaluated by venous sampling, ultrasonography, magnetic resonance imaging, or technetium-99m sestamibi scanning [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some evidence suggests that initial subtotal parathyroidectomy is associated with higher success rates with required reoperation for recurrent secondary hyperparathyroidism (87 versus 70 percent with initial total parathyroidectomy and immediate reimplantation in a report of 89 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Total parathyroidectomy without autotransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total parathyroidectomy without autotransplantation has the potential advantage of minimizing the chance of persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrent disease by removing all parathyroid tissue. However, after its institution in the 1960s, it quickly fell out of favor because of the following concerns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Development of adynamic bone disease and intractable osteomalacia",
"     </li>",
"     <li>",
"      Permanent hypoparathyroidism",
"     </li>",
"     <li>",
"      Impaired bone healing in the absence of PTH and its anabolic effects",
"     </li>",
"     <li>",
"      Need for long-term use of calcium and vitamin D",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In spite of these reservations, a majority of patients who undergo total parathyroidectomy have measurable PTH levels at long-term follow-up and no demonstrable bone disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. One report examined the long-term effects of total parathyroidectomy in 20 patients with refractory secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/46\">",
"     46",
"    </a>",
"    ]. Six patients had persistent hypocalcemia; five were asymptomatic, and one patient, who was not compliant with prescribed supplements, had two episodes of hypocalcemic seizures. Serum PTH concentrations were less than normal, normal, and increased in six, seven, and seven patients despite total parathyroidectomy.",
"   </p>",
"   <p>",
"    The origin of persisting PTH after total parathyroidectomy is not entirely clear. Missed supernumerary glands could explain a few cases. It is also presumed that small nests of parathyroid cells left behind at surgery undergo hyperplasia because of their continued exposure to the milieu of chronic renal failure.",
"   </p>",
"   <p>",
"    In summary, well designed, randomized, controlled trials comparing the three surgical techniques are lacking, and are unlikely to be performed. Each surgical technique carries its potential advantages and disadvantages. At present, there are insufficient data to warrant recommendation of one type of procedure over another. We do not recommend total parathyroidectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intraoperative PTH measurement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid PTH assay has quickly become a popular tool for intraoperative use in parathyroid surgery and for venous localization before surgery. It has been successfully used to guide limited parathyroidectomy in patients with primary hyperparathyroidism. With a turnaround time of less than 15 minutes, the rapid PTH assay works as a biochemical frozen section, providing the surgeon quantitative assurance that all hyperfunctioning parathyroid tissue has been removed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=see_link&amp;anchor=H10466887#H10466887\">",
"     \"Parathyroid exploration for primary hyperparathyroidism\", section on 'Intraoperative parathyroid hormone monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of intraoperative PTH monitoring during surgery for secondary hyperparathyroidism has not been well studied. In a series of 13 uremic patients with secondary hyperparathyroidism, the rapid PTH intraoperative assay demonstrated an 84 percent decrease in PTH levels after parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/47\">",
"     47",
"    </a>",
"    ]. In keeping with the data on primary hyperparathyroidism, there was excellent correlation between standard overnight immunoradiometric assay and the rapid intraoperative immunochemiluminometric assay.",
"   </p>",
"   <p>",
"    Although limited parathyroidectomy is not an option in patients with end-stage renal disease, since all glands are affected, potential benefits of intraoperative PTH monitoring include the detection of supernumerary glands and confirmation of an adequate degree of parathyroidectomy. Whether the rate of persistent or recurrent hyperparathyroidism after surgical parathyroidectomy will eventually be reduced as this technique is more widely used has yet to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ethanol injection under ultrasonographic guidance has been touted as a safe and simple approach to the treatment of refractory hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. After ultrasonographic identification of the parathyroid glands, ethanol is injected into the largest gland. The serum intact PTH concentration is measured one week after injection. If it is still more than 200",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    ethanol is injected into the same or next largest gland at one-week intervals until the intact PTH level falls to less than 200",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    One",
"    report described the results of 32 injections into 16 parathyroid glands in nine patients in whom pulse oral calcitriol therapy had failed to control hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/48\">",
"     48",
"    </a>",
"    ]. This approach in combination with continued calcitriol therapy resulted in control of hyperparathyroidism in seven patients.",
"   </p>",
"   <p>",
"    Another prospective study compared the results of surgery and ethanol injection in 39 dialysis patients with refractory hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 22 patients in whom percutaneous fine needle ethanol injection was performed, more than a 30 percent reduction in serum intact PTH was observed in 11. Four patients with an initial response subsequently had recurrent disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent laryngeal palsy occurred in four patients, which was permanent in two. In another series, transient recurrent laryngeal nerve palsy complicated 2 of 32 ethanol injections [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By comparison, success was achieved in all 17 patients who underwent surgical parathyroidectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, experience with ethanol injection is limited and the risk of complications uncertain. We believe that ethanol injection holds much promise, particularly if a single large gland is identified or in the treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy. However, this approach should be considered experimental until its efficacy and safety are established in a larger number of patients.",
"   </p>",
"   <p>",
"    A variation of this technique, which has been used by a Japanese group, consists of injection of calcitriol directly into enlarged parathyroid glands. Early results are encouraging, with a low morbidity rate and a surprisingly long duration of response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POST-SURGERY MORBIDITY AND MORTALITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hungry bone syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"hungry bone\" syndrome is the most common immediate complication of parathyroidectomy. This syndrome is characterized by a precipitous postoperative fall in the plasma concentrations of calcium and phosphorus. Tetany and seizures may ensue, possibly leading to major bone fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=see_link\">",
"     \"Hungry bone syndrome following parathyroidectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paucity of data exists concerning the long-term effect of parathyroidectomy on the risk of fracture. Although a number of single center case series have reported an increased bone mineral density after parathyroidectomy, the effect on fractures was not examined [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. To address this issue, a retrospective case control study evaluated the fracture risk for the hip and other locations among dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/57\">",
"     57",
"    </a>",
"    ]. Parathyroidectomy decreased the risk for hip fracture (0.68, 95% CI 0.54-0.86) and analyzed fracture (0.69, 95% CI 0.57-0.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a significant body of literature surrounding the impact on mortality of elevated parathyroid hormone levels, hyperphosphatemia, vascular calcification, and other clinical features associated with derangements of parathyroid function in end-stage renal disease. However, a paucity of data exists concerning survival following parathyroidectomy. In the largest study to address this issue (based upon data from the United States Renal Database System), an observational matched cohort study compared survival of 4558 dialysis patients who underwent a first parathyroidectomy with an equal number of control patients who did not undergo surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9273/abstract/58\">",
"     58",
"    </a>",
"    ]. Short-term mortality was higher among the parathyroidectomy group than controls (30 day post-operative mortality of 3.1 versus 1.2 percent); however, long-term survival was superior, with the median survival being 53 and 47 months for surgery and control groups, respectively.",
"   </p>",
"   <p>",
"    As with many major interventions, increased mortality can be observed soon after the procedure is performed. Possible reasons for improved long-term survival with surgery include a positive impact upon cardiovascular disease, better blood pressure control, and decreased reliance upon measures aimed at parathyroid hormone and phosphate control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2773660\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main indications for parathyroidectomy for hyperparathyroidism in dialysis patients include severe hypercalcemia, progressive and debilitating hyperparathyroid bone disease, pruritus that does not respond to medical or dialytic therapy, progressive extraskeletal calcification or calciphylaxis, or otherwise unexplained symptomatic myopathy. Since many of these problems can develop in dialysis patients without significant hyperparathyroidism, parathyroidectomy should not be performed unless very high PTH levels have been documented. Most dialysis patients undergoing parathyroidectomy have a serum intact PTH concentration above 800",
"      <span class=\"nowrap\">",
"       pg/mL.",
"      </span>",
"      Resistant anemia is not an independent indication for surgical intervention. Patients with persistent but modest elevations of PTH are usually managed medically. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for parathyroidectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parathyroidectomy is indicated in renal transplant recipients with persistent hyperparathyroidism in association with hypercalcemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progressive and otherwise unexplained renal insufficiency. Whether parathyroidectomy for severe hyperparathyroidism should be performed",
"      <strong>",
"       prior",
"      </strong>",
"      to renal transplantation is controversial. Overall the risk of persistent hyperparathyroidism seems to be too small to justify surgical intervention in all patients with severe secondary hyperparathyroidism on the transplant waiting list, since most do well. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Renal transplant recipients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of aluminum exposure and the presence of other forms of renal osteodystrophy (such as",
"      <span class=\"nowrap\">",
"       adynamic/aplastic",
"      </span>",
"      disease) should be considered when evaluating patients for parathyroidectomy. Both aluminum-associated low turnover bone disease and",
"      <span class=\"nowrap\">",
"       aplastic/adynamic",
"      </span>",
"      bone disease can mimic hyperparathyroidism by causing hypercalcemia, bone pain, and similar radiographic features. Parathyroidectomy can predispose to both aluminum-related osteomalacia and",
"      <span class=\"nowrap\">",
"       adynamic/aplastic",
"      </span>",
"      bone disease, especially if hypoparathyroidism is induced. We suggest that serum PTH values remain above 100",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      after parathyroidectomy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Aluminum exposure and other bone diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parathyroidectomy may lead to exacerbation of aluminum-induced osteomalacia. Transcortical iliac crest bone biopsy should be performed if there is uncertainty regarding the underlying bone disease or the presence of an aluminum burden. Preoperative bone biopsy is not recommended for patients with markedly elevated PTH levels who do not have a history of significant aluminum exposure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Aluminum exposure and other bone diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperparathyroidism may persist if four glands are not identified. Some physicians utilize radionuclide scanning to help detect hyperplastic parathyroid glands although it is not known whether or not this affects outcomes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical procedures that have been employed for the treatment of refractory hyperparathyroidism include subtotal parathyroidectomy, total parathyroidectomy with autotransplantation and total parathyroidectomy. There have been no randomized trials comparing these three techniques. Most surgeons perform either subtotal parathyroidectomy or total parathyroidectomy with autoimplantation, and among these two, there are insufficient data to warrant recommendation of one type of procedure over the other. We recommend not doing total parathyroidectomy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Surgical approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"hungry bone\" syndrome is the most common immediate complication of parathyroidectomy. This syndrome is characterized by a precipitous postoperative fall in the plasma concentrations of calcium and phosphorus. Tetany and seizures may ensue, possibly leading to major bone fractures. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hungry bone syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/1\">",
"      Kestenbaum B, Seliger SL, Gillen DL, et al. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int 2004; 65:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/2\">",
"      Foley RN, Li S, Liu J, et al. The fall and rise of parathyroidectomy in U.S. hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; 16:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/3\">",
"      Malberti F, Marcelli D, Conte F, et al. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001; 12:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/4\">",
"      Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/5\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/6\">",
"      Krause MW, Hedinger CE. Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum Pathol 1985; 16:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/7\">",
"      Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/8\">",
"      Zhang P, Duchambon P, Gogusev J, et al. Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 2000; 57:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/9\">",
"      Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/10\">",
"      Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/11\">",
"      Yasunaga C, Nakamoto M, Matsuo K, et al. Effects of a parathyroidectomy on the immune system and nutritional condition in chronic dialysis patients with secondary hyperparathyroidism. Am J Surg 1999; 178:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/12\">",
"      Tzanno-Martins C, Futata E, Jorgetti V, Duarte AJ. Restoration of impaired T-cell proliferation after parathyroidectomy in hemodialysis patients. Nephron 2000; 84:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/13\">",
"      Pizzarelli F, Fabrizi F, Postorino M, et al. Parathyroidectomy and blood pressure in hemodialysis patients. Nephron 1993; 63:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/14\">",
"      Ifudu O, Matthew JJ, Macey LJ, et al. Parathyroidectomy does not correct hypertension in patients on maintenance hemodialysis. Am J Nephrol 1998; 18:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/15\">",
"      Tominaga Y, Tanaka Y, Sato K, et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/16\">",
"      Ritz E. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? II. Early parathyroidectomy should be considered as the first choice. Nephrol Dial Transplant 1994; 9:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/17\">",
"      Jofr&eacute; R, L&oacute;pez G&oacute;mez JM, Men&aacute;rguez J, et al. Parathyroidectomy: whom and when? Kidney Int Suppl 2003; :S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/18\">",
"      Katoh N, Nakayama M, Shigematsu T, et al. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 2000; 35:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/19\">",
"      Rault R, Magnone M. The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis. ASAIO J 1996; 42:M901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/20\">",
"      Garcia-Canton C, Palomar R, Moreno A, et al. Evolution of anemia of chronic renal failure after the treatment of hyperparathyroidism. Nephron 1996; 74:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/21\">",
"      Schmid T, M&uuml;ller P, Spelsberg F. Parathyroidectomy after renal transplantation: a retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997; 12:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/22\">",
"      Rostaing L, Moreau-Gaudry X, Baron E, et al. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism. Clin Nephrol 1997; 47:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/23\">",
"      Chan YL, Posen S, Savdie E, et al. Total parathyroidectomy and renal function in patients with chronic renal failure. Miner Electrolyte Metab 1983; 9:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/24\">",
"      Tzanakis I, Alifieris E, Kagia S, et al. Does parathyroidectomy affect residual diuresis in hemodialysis patients? Nephron 2000; 86:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/25\">",
"      Hercz G, Pei Y, Greenwood C, et al. Aplastic osteodystrophy without aluminum: the role of \"suppressed\" parathyroid function. Kidney Int 1993; 44:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/26\">",
"      Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987; 31:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/27\">",
"      Andress DL, Ott SM, Maloney NA, Sherrard DJ. Effect of parathyroidectomy on bone aluminum accumulation in chronic renal failure. N Engl J Med 1985; 312:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/28\">",
"      Akerstr&ouml;m G, Malmaeus J, Bergstr&ouml;m R. Surgical anatomy of human parathyroid glands. Surgery 1984; 95:14.",
"     </a>",
"    </li>",
"    <li>",
"     Wells, SA Jr, Ashley SW. The parathyroid glands. In: Textbook of Surgery, 14th ed, Sabiston, DC Jr (Ed), Saunders, Philadelphia, 1991, pp. 598-615.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/30\">",
"      Takagi H, Tominaga Y, Uchida K, et al. Subtotal versus total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 1984; 200:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/31\">",
"      Rothmund M, Wagner PK. Reoperations for persistent and recurrent secondary hyperparathyroidism. Ann Surg 1988; 207:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/32\">",
"      Kaye, M. Parathyroid surgery in renal failure: A review. Semin Dial 1990; 3:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/33\">",
"      Gagn&eacute; ER, Ure&ntilde;a P, Leite-Silva S, et al. Short- and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992; 3:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/34\">",
"      Neumann DR, Esselstyn CB Jr, Madera A, et al. Parathyroid detection in secondary hyperparathyroidism with 123I/99mTc-sestamibi subtraction single photon emission computed tomography. J Clin Endocrinol Metab 1998; 83:3867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/35\">",
"      Hindi&eacute; E, Uren&atilde; P, Jeanguillaume C, et al. Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism. Lancet 1999; 353:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/36\">",
"      P&eacute;ri&eacute; S, Fessi H, Tassart M, et al. Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism. Am J Kidney Dis 2005; 45:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/37\">",
"      Cattan P, Halimi B, A&iuml;dan K, et al. Reoperation for secondary uremic hyperparathyroidism: are technical difficulties influenced by initial surgical procedure? Surgery 2000; 127:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/38\">",
"      Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg 1991; 15:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/39\">",
"      Kaye M, D'Amour P, Henderson J. Elective total parathyroidectomy without autotransplant in end-stage renal disease. Kidney Int 1989; 35:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/40\">",
"      Llach F. Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int Suppl 1990; 29:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/41\">",
"      Tominaga Y, Tanaka Y, Sato K, et al. Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World J Surg 1992; 16:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/42\">",
"      Casanova D, Sarfati E, De Francisco A, et al. Secondary hyperparathyroidism: diagnosis of site of recurrence. World J Surg 1991; 15:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/43\">",
"      Rodriquez JM, Tezelman S, Siperstein AE, et al. Localization procedures in patients with persistent or recurrent hyperparathyroidism. Arch Surg 1994; 129:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/44\">",
"      Kaye M, Rosenthall L, Hill RO, Tabah RJ. Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol 1993; 39:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/45\">",
"      Ljuti�� D, Cameron JS, Ogg CS, et al. Long-term follow-up after total parathyroidectomy without parathyroid reimplantation in chronic renal failure. QJM 1994; 87:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/46\">",
"      Stracke S, Jehle PM, Sturm D, et al. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999; 33:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/47\">",
"      Clary BM, Garner SC, Leight GS Jr. Intraoperative parathyroid hormone monitoring during parathyroidectomy for secondary hyperparathyroidism. Surgery 1997; 122:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/48\">",
"      Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/49\">",
"      Giangrande A, Castiglioni A, Solbiati L, Allaria P. Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 1992; 7:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/50\">",
"      Kakuta T, Fukagawa M, Fujisaki T, et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999; 33:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/51\">",
"      Fassi J, Lambertini R, Farias P, et al. Treatment of uremic hyperparathyroidism with percutaneous ethanol injection. Nephron Clin Pract 2005; 101:c53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/52\">",
"      Fletcher S, Kanagasundaram NS, Rayner HC, et al. Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Nephrol Dial Transplant 1998; 13:3111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/53\">",
"      Kitaoka M, Onoda N, Kitamura H, et al. Percutaneous calcitriol injection therapy (PCIT) for secondary hyperparathyroidism: multicentre trial. Nephrol Dial Transplant 2003; 18 Suppl 3:iii38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/54\">",
"      Abdelhadi M, Nordenstr&ouml;m J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998; 83:3845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/55\">",
"      Chou FF, Chen JB, Lee CH, et al. Parathyroidectomy can improve bone mineral density in patients with symptomatic secondary hyperparathyroidism. Arch Surg 2001; 136:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/56\">",
"      Yano S, Sugimoto T, Tsukamoto T, et al. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain. Horm Metab Res 2003; 35:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/57\">",
"      Rudser KD, de Boer IH, Dooley A, et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9273/abstract/58\">",
"      Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66:2010.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1838 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9273=[""].join("\n");
var outline_f9_3_9273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2773660\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS OF REFRACTORY HYPERPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR PARATHYROIDECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Aluminum exposure and other bone diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SURGICAL APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Subtotal versus total parathyroidectomy with autotransplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Site of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Total parathyroidectomy without autotransplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intraoperative PTH measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERCUTANEOUS TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POST-SURGERY MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hungry bone syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2773660\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1838|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/35/17982\" title=\"figure 1\">",
"      Effects of parathyroidectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28343?source=related_link\">",
"      Bone biopsy and the diagnosis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15017?source=related_link\">",
"      Calciphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3287?source=related_link\">",
"      Hungry bone syndrome following parathyroidectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/58/32681?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/0/35850?source=related_link\">",
"      Parathyroid exploration for primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18377?source=related_link\">",
"      Preoperative localization for parathyroid surgery in patients with primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6937?source=related_link\">",
"      Uremic pruritus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9274="Pathogenesis and treatment of malnutrition in maintenance dialysis";
var content_f9_3_9274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and treatment of malnutrition in maintenance dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9274/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9274/contributors\">",
"     Marsha Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9274/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/3/9274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/3/9274/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/3/9274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is an important problem in patients treated with chronic hemodialysis or peritoneal dialysis. It occurs in 20 to 70 percent of patients (depending upon the method used to measure nutritional status), with an increasing length of time on dialysis correlating with an increasing decline in nutritional parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be significant differences between countries with respect to some measures of nutritional status, such as serum albumin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/4\">",
"     4",
"    </a>",
"    ]. Based upon the Dialysis Outcomes and Practice Patterns Study (DOPPS), for example, the following mean serum albumin levels were reported in France (3.87",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    Germany (4.17",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    Italy (3.98",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    Spain (3.98",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    United States (3.6",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    and the United Kingdom (3.72",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/4\">",
"     4",
"    </a>",
"    ]. However, since differences in measurement methods cause differences in results, the method used from laboratory to laboratory and country to country must be known to assess any true differences in serum albumin in an individual patient or groups of patients.",
"   </p>",
"   <p>",
"    Two important issues are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How is nutritional status evaluated? (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"       \"Assessment of nutritional status in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      What is the relation between nutritional status and survival? Patients with malnutrition, as manifested in part by hypoalbuminemia, measured at the onset of or during maintenance dialysis, have an increased mortality rate (",
"      <a class=\"graphic graphic_figure graphicRef60944 graphicRef70749 \" href=\"UTD.htm?29/33/30238\">",
"       figure 1A-B",
"      </a>",
"      ). This is true for patients treated with either maintenance hemodialysis or peritoneal dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/5-8\">",
"       5-8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"       \"Patient survival and maintenance dialysis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis, prevention, and treatment of malnutrition in these patients will be discussed here. Most of the observations have been made in patients treated with maintenance hemodialysis, but similar considerations apply in many respects to continuous peritoneal dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most readily treatable cause of inadequate nutrition in many patients is underdialysis, which can lead to anorexia and decreased taste acuity. Patients with a minimally acceptable",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and a low mid-week BUN may appear, at first glance, to be well dialyzed. However, many such patients are underdialyzed with poor protein intake being responsible for the low BUN.",
"   </p>",
"   <p>",
"    This problem eventually led to the appreciation that protein intake must be considered when evaluating the adequacy of dialysis. Thus, estimation of the normalized protein equivalence of nitrogen appearance (nPNA), as index of protein intake, is a part of the dialysis regimen. This is also known as the normalized protein catabolic rate (nPCR). The PCR is only valid as a measure of protein intake in the patient in neutral nitrogen balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between the dose of dialysis and protein intake was demonstrated in a small group of hemodialysis patients in whom the intensity of dialysis was increased by enhancing dialysis time, blood flow,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    membrane surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/9\">",
"     9",
"    </a>",
"    ]. As the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    rose from 0.82 to 1.32 over a three month period, there was a concurrent elevation in PCR from 0.81 to 1.02",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. The rise in PCR was indicative of increased protein intake (and better nutrition) due, presumably, to improved appetite. A second group in which the dialysis regimen was unchanged had no increase in either",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or PCR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .) Whether there is a mathematical link between",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and PCR because they are both calculated from similar measures is a subject of debate.",
"   </p>",
"   <p>",
"    Further support for the observation of improved nutritional intake with increased dialysis dose was reported in a study in which improved body weight was observed with more frequent daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/10\">",
"     10",
"    </a>",
"    ]. An increased dialysis dose may also enhance nutritional status among malnourished peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in the well-dialyzed patient, however, a number of factors can impair nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of an acute, chronic, or occult systemic illness leading to an inflammatory response may adversely impact nutritional status. Markedly increased energy expenditure, proinflammatory cytokine levels, and oxidative stress appear to provide a link between inflammation and malnutrition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"       \"Inflammation in renal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nutrients are lost into the dialysate. As an example, amino acid losses into dialysate can average 4 to 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      with peritoneal dialysis or hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. With peritoneal dialysis, losses rise much higher during episodes of peritonitis. [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/17\">",
"       17",
"      </a>",
"      ]. With hemodialysis, certain reuse procedures result in increased losses of protein into dialysate. Protein loss as high as 20 grams in one hemodialysis has been reported with polysulfone dialyzers reused with bleach [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dietary restrictions can make food less palatable. Furthermore, the encouragement to restrict fluid intake to minimize intradialytic weight gain may lead to a concurrent decrease in caloric intake [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/20\">",
"       20",
"      </a>",
"      ]. Solid food has a high fluid content and many beverages contain a substantial amount of calories.",
"     </li>",
"     <li>",
"      The dialysis procedure itself may be catabolic, due to reduced protein synthesis and the loss of amino acids in dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/21\">",
"       21",
"      </a>",
"      ]; this effect may be more prominent with bioincompatible membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/22\">",
"       22",
"      </a>",
"      ]. This can be overcome with appropriate nutritional intake.",
"     </li>",
"     <li>",
"      As shown in some, but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/23\">",
"       23",
"      </a>",
"      ], studies, persistent metabolic acidosis may enhance protein degradation and amino acid oxidation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"       \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastroparesis (by slowing gastric emptying) or, in peritoneal dialysis, the presence of dialysate in the abdomen may impart a feeling of fullness.",
"     </li>",
"     <li>",
"      Some medications, such as phosphate binders, can impair nutrient absorption.",
"     </li>",
"     <li>",
"      Adequate dialysis is not a complete substitute for the clearance functions of an intact kidney. In particular, the retention of middle molecules (1000 to 5000 Daltons) may in part contribute to anorexia, possibly by directly affecting the central nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum concentrations of leptin, a hormone that induces satiety via effects upon the hypothalamus, may be increased due to reduced renal or dialysis clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/27-29\">",
"       27-29",
"      </a>",
"      ]. However, a role for leptin in malnutrition in the dialysis patient remains to be proven. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=see_link\">",
"       \"Pathogenesis of obesity\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33591?source=see_link\">",
"       \"Leptin and end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic volume overload may be directly associated with malnutrition, with improved fluid status increasing overall nutritional status [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of both malnutrition and extremely low levels of renal function at the time of dialysis initiation are directly associated with subsequent poor nutritional status despite adequate dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/33\">",
"       33",
"      </a>",
"      ]. This observation suggests that dialysis should be begun prior to the onset of significant malnutrition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"       \"Indications for initiation of dialysis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the prevention of malnutrition is careful assessment of the patient's nutritional status at the beginning of dialysis and every three to six months thereafter. Early diagnosis and correction can avoid clinical deterioration that may make the patient more difficult to treat, in part because malnutrition itself may lead to anorexia. This relationship is suggested by studies in which improved nutritional status led to improved food intake. In one report, for example, malnourished patients on hemodialysis received parenteral nutrition supplements during the dialysis procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/34\">",
"     34",
"    </a>",
"    ]. This led to an increase in food intake, which began before any changes could be demonstrated in nutritional status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ingestion of an adequate diet is very important if malnutrition is to be prevented. Patients previously on a low-protein diet may need to be reminded to increase protein intake once dialysis begins to counteract protein loss in the dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/15\">",
"     15",
"    </a>",
"    ]. Although somewhat controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/35\">",
"     35",
"    </a>",
"    ], a diet providing 1.0 to 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of high biologic value protein is recommended for patients on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous ambulatory peritoneal dialysis is associated with a higher level of dialysate protein loss [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/17\">",
"     17",
"    </a>",
"    ]; as a result, protein intake should be at least 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day with this treatment modality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/38\">",
"     38",
"    </a>",
"    ]. One study demonstrated that the metabolic response to protein intake is normal in hemodialysis patients, further supporting the importance of maintaining adequate dietary protein intake [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adequate caloric intake also must be emphasized, since it is required for anabolism. In one study, for example, patients on maintenance hemodialysis were studied on different diets [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/40\">",
"     40",
"    </a>",
"    ]. There was negative nitrogen balance unless caloric intake was at least 32",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    ideal body weight (",
"    <a class=\"graphic graphic_figure graphicRef77072 \" href=\"UTD.htm?12/39/12926\">",
"     figure 2",
"    </a>",
"    ). For patients treated with peritoneal dialysis, the calories provided by the dialysis solution should be taken into account.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of malnutrition is usually suspected from anthropometry or the presence of hypoalbuminemia or decreased creatinine production. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .) Evaluation should begin with a thorough history to determine whether the reduction in food intake is caused by unpalatable dietary restrictions or by changes in the patient's sense of taste. The dietary history should include personal or ethnic food preferences. If limiting such preferences is interfering with food intake, the clinician or dietitian should work with the patient and family to add more preferred foods to the diet. In cases of severe malnutrition, most or all dietary limitations may have to be removed for a limited period of time.",
"   </p>",
"   <p>",
"    In general, if malnutrition is diagnosed, we suggest the following stepped treatment strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of any source of inflammation should be sought and managed.",
"     </li>",
"     <li>",
"      Dietary intake should be assessed and dietary counseling should be undertaken.",
"     </li>",
"     <li>",
"      If the patient cannot improve nutrient intake by diet alone, intake should be improved in a step-wise fashion, starting with oral supplements and ending with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      if no other nutrient intake methodology is appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Drug toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that can impair appetite or make meals less palatable should be reduced or eliminated. In severe cases, the patient may benefit from temporary cessation of oral phosphate binders. Hyperphosphatemia is a lesser risk in this setting, since the low protein intake itself will lower the plasma phosphate concentration. In fact, hypophosphatemia may be an additional clue to the presence of malnutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gastroparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroparesis can be contributing factor to decreased food intake by delaying gastric emptying, thereby increasing the feeling of fullness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=see_link\">",
"     \"Gastrointestinal disease in dialysis patients\"",
"    </a>",
"    .) This complication is most common in diabetics (possibly affecting as many as 20 to 30 percent of diabetics with end-stage renal disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/41\">",
"     41",
"    </a>",
"    ], but can also occur in nondiabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. If gastroparesis is suspected from the history, the rate of gastric emptying can be accurately assessed by various methods, such as ingestion of a radiolabeled test meal with simultaneous gastric scanning. If slow or delayed gastric emptying is documented, several therapeutic modalities may be beneficial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       Metoclopramide",
"      </a>",
"      can be given, but the dose must be limited in patients with end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients have been successfully treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=see_link\">",
"       \"Diabetic autonomic neuropathy of the gastrointestinal tract\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients not responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      may respond to other agents, such as cisapride&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/47\">",
"       47",
"      </a>",
"      ]. However, the use of cisapride is now restricted per the manufacturer's and Federal Drug Administration's recommendations due to the risk of arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/48\">",
"       48",
"      </a>",
"      ]. As of August 2000, prescriptions for the drug can only be filled directly through the manufacturer after providing documentation as to need for the drug and assessment of risk factors for cardiac arrhythmias in the individual patient (including a prolonged QTc on the EKG or use of medications known to alter the drug's metabolism such as macrolide antibiotics, antifungals and phenothiazines).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If gastroparesis is detected via gastric emptying scans, the optimal therapeutic agent may be chosen based upon the prokinetic response to an intravenous test dose. As an example, the gastric emptying response to intravenous doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (5 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (200 mg) was assessed in 6 dialysis patients with hypoalbuminemia and occult gastroparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/49\">",
"     49",
"    </a>",
"    ]. Subsequent oral therapy based upon a successful gastric response significantly improved serum albumin levels (from 3.3 to 3.7",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nutritional supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;If attention to the preceding problems does not improve appetite and food intake, then nutritional supplementation may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/15,50,51\">",
"     15,50,51",
"    </a>",
"    ]. Oral supplementation, enteral tube feeding, and parenteral nutrition are all possibilities. A 2005 systematic review and meta-analysis of 18 studies (including five randomized controlled trials) found that enteral nutritional support increased total intake and serum albumin concentration (0.23",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/52\">",
"     52",
"    </a>",
"    ]. Clinical outcomes were evaluated in only a few studies, while data was inadequate to compare both disease-specific versus standard formulae and enteral versus parenteral nutrition.",
"   </p>",
"   <p>",
"    Oral supplements are the easiest and cheapest to use. Several supplements are intended primarily for the patient with end-stage renal disease. They are low in potassium and fairly dense in nutrients, thereby providing adequate calories and protein, while minimizing the risk of hyperkalemia and fluid overload. However, these supplements have the disadvantage of being more costly than less specific preparations, thereby making compliance an issue.",
"   </p>",
"   <p>",
"    Oral supplements provided at the time of dialysis treatments may be an effective therapy. This was suggested by a matched cohort study of maintenance hemodialysis patients with serum albumin concentrations &le;3.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    who were provided with oral nutritional supplements at the time of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/53\">",
"     53",
"    </a>",
"    ]. By 15 months of follow-up, improved survival was demonstrated among patients given oral nutritional supplements compared with untreated matched control patients by both as-treated and intention-to-treat analysis. The greatest benefit of oral supplements was observed among patients with the lowest baseline serum albumin concentration (&le;3.2",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    These observations, although potentially clinically significant, are limited by the absence of random allocation of patients; although control patients were matched by propensity score, residual confounding remains possible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study analyzed the effect of providing oral supplements (taken at non-dialysis times) to patients with serum albumin &le;3.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/55\">",
"     55",
"    </a>",
"    ]. This was a retrospective analysis of data provided by Fresinius Medical Health Care Plan&rsquo;s disease management program, in which eligible patients (ie, defined as those with serum albumin &le;3.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    for two or more months) were provided with 24 cans of oral supplement per month. Among eligible patients, 276 received supplements and 194 did not, either because it was deemed inappropriate for unspecified reasons, or because they refused. After multiple adjustments, compared with no supplements, the use of oral supplements was associated with a lower rate of hospitalization (89 versus 68 percent respectively), and with a nonsignificant trend toward improved survival at one year (p = 0.09) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/55\">",
"     55",
"    </a>",
"    ]. This study was limited by the possible presence of unadjusted differences in the patient populations.",
"   </p>",
"   <p>",
"    Despite the limitations associated with both studies cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/53,55\">",
"     53,55",
"    </a>",
"    ], oral nutritional supplements administered during the dialysis treatment may be a useful intervention for some patients with very low serum albumin. Compared with intravenous nutritional supplementation, oral supplementation has fewer side effects, is more cost-effective, and appears to be a reasonable first step in the nutrition management of these patients.",
"   </p>",
"   <p>",
"    The general supplements can be tried in patients able to tolerate the increase in potassium and fluid intake. We limit the specific \"renal failure\" supplements to patients with preexisting hyperkalemia or fluid overload due, for example, to heart failure. Although some evidence suggests that oral essential amino acids may be modestly beneficial to patients with significant hypoalbuminemia, further study is needed prior to any recommendation concerning their use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/15,56\">",
"     15,56",
"    </a>",
"    ]. Patient compliance is important to the success of oral nutrient supplements.",
"   </p>",
"   <p>",
"    A different regimen is required in patients with severe anorexia who are unable to increase their oral intake. Overnight supplementation by nasoenteral feeding tube may be effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/50,57\">",
"     50,57",
"    </a>",
"    ]. A short course of overnight tube feeding can lead to a sufficient improvement in nutritional status and overall well-being that adequate dietary oral can be resumed.",
"   </p>",
"   <p>",
"    Patients with severe gastroparesis may be unable to tolerate any form of oral supplementation. Intradialytic parenteral nutrition (IDPN) may be beneficial in this setting if the malnutrition is not too severe. IDPN solutions are similar those used for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    : a typical solution contains 10 percent amino acids and 40 to 50 percent glucose, 10 to 20 percent lipids, or a mixture of carbohydrate or lipids depending upon the needs of the patient.",
"   </p>",
"   <p>",
"    However, IDPN has certain limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is the most costly and least efficient nutritional supplement. IDPN often costs twice as much as dialysis itself, and only 70 percent of the nutrients are actually delivered to the patient because of loss into the dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malnutrition may persist, since IDPN is administered only three days per week for approximately 4 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It may be associated with a lower than expected delivered dose of dialysis, due possibly to increased urea generation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these shortcomings, IDPN is convenient (because it is delivered during dialysis) and is likely to be beneficial in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/60\">",
"     60",
"    </a>",
"    ]. However, although a number of studies suggest that IDPN provides substantial benefit, most were case reports, retrospective, or poorly designed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. To better assess the effects of IDPN, 186 malnourished hemodialysis patients were randomly assigned to oral nutritional supplements, with or without one year of IDPN [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/64\">",
"     64",
"    </a>",
"    ]. At two years, there was no difference in mortality, hospitalization rate, and nutritional status between the two groups. With multivariate analysis, however, improved nutrition defined as an increase in prealbumin level of greater than 30",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    within the first three months correlated with an approximately 50 percent decrease in mortality at two years.",
"   </p>",
"   <p>",
"    The optimal indications for IDPN have not been established. We consider use of this modality in the malnourished dialysis patient who cannot tolerate oral supplements but who can consume at least 50 percent of the prescribed caloric intake. This is consistent with the 2007 European best practice guidelines for hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If this degree of oral intake cannot be reached, we first try a nasoenteral feeding tube with nighttime enteral nutrition or, if oral intake is not tolerated, the institution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     Total parenteral nutrition",
"    </a>",
"    (TPN) is required in the rare patient with severe malabsorption, severe malnutrition, or severe intolerance of oral supplements. Although generally well tolerated, TPN solutions typically contain added potassium, phosphorus, and magnesium. Thus, patients with end-stage renal disease receiving TPN are at risk for the development of hyperkalemia, hyperphosphatemia, and hypermagnesemia. Elimination of the added electrolytes can prevent these problems but carries the reverse risk of electrolyte deficiencies with prolonged therapy.",
"   </p>",
"   <p>",
"    We generally recommend that TPN be started with solutions containing little or no added electrolytes. The patient should then be carefully monitored, and electrolytes should be added if the plasma levels fall below the normal range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dialysis prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialysis prescription should be reassessed in terms of",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    and the protein catabolic rate. In an attempt to address the question of optimal dialysis dose and membrane flux for hemodialysis patients, a large clinical trial, called the Hemodialysis (HEMO) Study, was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients were randomly assigned to a standard (single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.25) or high dose of dialysis (single-pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    of 1.65) and a low- or high-flux dialyzer. Similar outcomes in terms of survival were observed with high and standard dialysis doses as well as dialysis using high and low flux membranes. Subsequent analysis of the HEMO trial also found that nutritional parameters, such as serum albumin and anthropometric measures, were the same with the different dose and flux interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current minimum recommendations are 1.3 to 1.4 for",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    in hemodialysis, at least 1.7 for weekly",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    in continuous ambulatory peritoneal dialysis, and 1.0 to 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day for the nPNA. There is also some preliminary evidence that, compared with",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    Kt alone (which is the non-normalized dialysis dose) may be more closely associated with serum albumin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although further study is required, daily in center and nocturnal hemodialysis have been used as a rescue therapy for patients with severe malnutrition complicating uremia, with patients generally reporting increased appetite after switching from conventional to daily dialysis. The effects on nutrition of short daily and nocturnal hemodialysis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recombinant human growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies suggest that administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    can reduce wasting and catabolism, improve nutritional status, and lower the BUN in hemodialysis patients, even in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/68-71\">",
"     68-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 139 adult dialysis patients with serum albumin levels less than 4",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      were randomly assigned to six months of therapy with different doses of recombinant growth hormone or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/71\">",
"       71",
"      </a>",
"      ]. Lean body mass significantly increased at all dose levels (2.5 kg versus &ndash;0.4 kg) for placebo, while serum albumin levels tended to increase.",
"     </li>",
"     <li>",
"      In another prospective, cross-over study, improvements in protein metabolism were observed with administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      when compared to no hormone therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/69\">",
"       69",
"      </a>",
"      ], as shown by a decrease in BUN (55 versus 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [19.6 versus 14.3",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and a decrease in protein catabolic rate (0.82 versus 0.67",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day). Follow-up evaluation of these patients revealed that the improved protein metabolism resulted from the increased ability to utilize essential amino acids [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/72\">",
"       72",
"      </a>",
"      ]. Similar improvements in protein metabolism were noted in other studies in which the benefit from recombinant human growth hormone could largely be explained by an increase in free insulin-like growth factor-1 levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/73,74\">",
"       73,74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     Recombinant human growth hormone",
"    </a>",
"    has also been reported to improve nutritional status in malnourished patients on hemodialysis treated with IDPN; the latter was ineffective when given alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/75\">",
"     75",
"    </a>",
"    ]. Recombinant insulin-like growth factor-1 (IGF-1) has also been shown to markedly increase nitrogen balance in patients treated with CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite evidence suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    provides short term benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/69,70,72-74,77,78\">",
"     69,70,72-74,77,78",
"    </a>",
"    ], significant long-term nutritional benefits with this agent are not consistently observed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/79\">",
"     79",
"    </a>",
"    ]. In addition, the effects of recombinant human growth hormone on malnutrition associated morbidity and mortality are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/15\">",
"     15",
"    </a>",
"    ]. One additional major limitation of the use of recombinant therapy for the treatment of malnutrition in patients with ESRD is its very high cost.",
"   </p>",
"   <p>",
"    To best assess the benefits and adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    , the OPPORTUNITY trial will assess the effect of this hormone on survival in hypoalbuminemic dialysis patients and its effect upon morbidity, markers of body protein mass, inflammation, exercise capacity, and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Correction of acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremic acidosis can increase skeletal muscle breakdown and diminish albumin synthesis, leading to muscle wasting and muscle weakness. Recommendations concerning correction of acidosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenic anabolic steroids and anti-inflammatory drugs have been used in dialysis patients with malnutrition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only limited data have evaluated the efficacy and adverse effects of androgenic anabolic steroids in dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/81-83\">",
"       81-83",
"      </a>",
"      ]. Although an increase in body weight, muscle mass, and serum albumin have been reported, the long-term efficacy and risk for adverse effects with these agents is unclear. These agents therefore cannot be recommended in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of anti-inflammatory agents in patients with malnutrition-inflammation syndrome complex is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"       \"Inflammation in renal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis patients often have decreased taste acuity, which is controversially associated with zinc deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/84\">",
"       84",
"      </a>",
"      ]. If present, diminished taste acuity can lead to decreased intake and anorexia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/85\">",
"       85",
"      </a>",
"      ]. The role of zinc deficiency has never been established and we do not routinely measure plasma zinc levels or administer zinc supplements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MALNUTRITION IN CONTINUOUS AMBULATORY PERITONEAL DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the foregoing discussion applies to both hemodialysis and peritoneal dialysis. As previously noted, however, there are several problems unique to peritoneal dialysis, including increased dialysate protein losses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/17\">",
"     17",
"    </a>",
"    ] and a feeling of fullness due to dialysate in the abdomen. Gastroparesis is also more common, since many CAPD patients are diabetic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10614?source=see_link\">",
"     \"Dialysis in diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of malnutrition in these patients again focuses on prevention and treatment. The approach is similar to that noted above, but there are a number of specific recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with loss of appetite should drain the dialysate just before meals so that the abdomen is empty at mealtime. They may also tolerate frequent, small meals better than the usual three large meals.",
"     </li>",
"     <li>",
"      Peritoneal dialysis patients generally have fewer dietary restrictions than those treated with hemodialysis, since they are continuously dialyzed. However, some patients consume excessive amounts of fluid that are removed by the use of high-dextrose dialysate. The ensuing increase in glucose absorption can, in susceptible subjects, lead to hyperglycemia, which can directly suppress appetite [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. Avoidance of excess fluid intake is therefore desirable, since it limits the necessity for use of hypertonic dialysis solutions.",
"     </li>",
"     <li>",
"      Persistent malnutrition can be treated with oral supplements or TPN. Limited data, however, have reported mixed results with oral nutritional supplementation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/88-90\">",
"       88-90",
"      </a>",
"      ]; this is possibly the result of poor compliance, small sample size, and reliance upon serum albumin concentration as the principal outcome measure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/91\">",
"       91",
"      </a>",
"      ]. Clearly, IDPN is not feasible due to continuous dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Amino acid dialysate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysate containing amino acids as the osmotic agent, rather than glucose, may minimize some of these above problems, increasing net protein intake, allowing the attainment of positive nitrogen balance and net anabolism and improving the plasma albumin concentration and overall nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/92-96\">",
"     92-96",
"    </a>",
"    ]. In a prospective three month study, 105 malnourished peritoneal dialysis patients were randomly assigned to one or two exchanges per day with a 1.1 percent amino acid dialysate, or to usual therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/94\">",
"     94",
"    </a>",
"    ]. Benefits observed in the group receiving the protein dialysate included increases in insulin-like growth factor-1, and decreases in serum potassium and inorganic phosphorus, findings indicative of a general anabolic response.",
"   </p>",
"   <p>",
"    The combination of amino acid plus glucose dialysate may also improve the nutritional status of malnourished patients. In a random order crossover study of eight patients undergoing nocturnal automated peritoneal dialysis, protein kinetics was markedly superior over a one week period with dialysate containing amino acid plus glucose versus that observed during a week with the control dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/97\">",
"     97",
"    </a>",
"    ]. Further study in a larger number of patients is required to adequately evaluate this approach.",
"   </p>",
"   <p>",
"    Dialysate containing amino acids as the osmotic agent is now commercially available in Europe, Canada and other regions, although they are not commercially available in the United States. Patients who are treated with amino acid containing dialysate should be monitored closely for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To avoid amino acid imbalance, amino acid dialysate should not be used for more than one or at most two exchanges per day [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/92,93\">",
"       92,93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As the osmotic agent, a 1.1 percent solution of amino acids has an ultrafiltration profile similar to dialysis solutions containing 1.5 percent dextrose. Thus, amino acid dialysate should not be used for the overnight dwell because most of the amino acids will be absorbed, thereby limiting the degree of fluid removal.",
"     </li>",
"     <li>",
"      There is concern that amino acids will raise urea nitrogen appearance and urea production if they are not used for anabolism. Amino acid dialysate may also lead to metabolic acidosis which is primarily due to the hydrogen ion contained in cationic amino acids (such as lysine) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/93\">",
"       93",
"      </a>",
"      ]. Thus, both the BUN, and plasma bicarbonate concentration should be monitored.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The European Best Practice Guidelines suggest that an amino acid containing solution should be considered in malnourished patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/98\">",
"     98",
"    </a>",
"    ]. They also state that this solution should only be used once daily.",
"   </p>",
"   <p>",
"    Malnourished patients who do not tolerate oral supplements are most likely to benefit. A response &mdash; improved appetite, increased plasma albumin concentration, weight gain &mdash; should be seen within three months; at this time, we switch back to conventional dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Enteral tube feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some PD patients with malnutrition who are unable to ingest adequate amounts of nutrition have been successfully treated with enteral tube feedings, particularly with gastrostomy or gastrojejunostomy tubes. A paucity of data exists concerning the use of this method of feeding in adults, but it appears to result in improved nutrition in malnourished children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that improved control of metabolic acidosis may enhance the nutritional status in peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. In one study, 200 consecutive patients initiating peritoneal dialysis were randomized to high (lactate of 40",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    or low (35",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    alkali dialysate for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/100\">",
"     100",
"    </a>",
"    ]. Correction of acidosis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    was also utilized in the high alkali group. At one year, the serum bicarbonate in the high alkali group was 27",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    versus 23",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the low alkali group. Compared to the low alkali group, benefits observed with high alkali therapy included a greater increase in body weight (6.1 versus 3.7 kg, P&lt;0.05) and lower morbidity (16.4 versus 21.2 days spent in the hospital, P&lt;0.05).",
"   </p>",
"   <p>",
"    A preliminary study found that administration of ghrelin, a hormone that functions as an appetite enhancer, may enhance food intake acutely in malnourished patients undergoing peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/3/9274/abstract/102\">",
"     102",
"    </a>",
"    ]. Longer term study is required to better characterize the effects of ghrelin in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=see_link\">",
"       \"Patient information: Dialysis and diet (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malnutrition is common in patients treated with maintenance dialysis. Principal causes include inadequate dialysis dose, inflammation, dietary restrictions, nutrients lost via dialysate, catabolic properties of dialysis, and other factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in the prevention of malnutrition is careful assessment of the patient's nutritional status at the beginning of dialysis and every three to six months thereafter. Ingestion of an adequate diet is very important if malnutrition is to be prevented. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If malnutrition is diagnosed, it is important to undertake treatment strategies as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evaluation of any source of inflammation should be sought and managed.",
"     </li>",
"     <li>",
"      Dietary intake should be assessed and dietary counseling should be undertaken.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient cannot improve nutrient intake by diet alone, intake should be improved in a step-wise fashion, starting with oral supplements and ending with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      if no other nutrient intake methodology is appropriate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Much of the discussion related to malnutrition in this topic review applies to both hemodialysis and peritoneal dialysis. However, since there are several problems unique to peritoneal dialysis, a number of specific recommendations can be made in these patients. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Malnutrition in continuous ambulatory peritoneal dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/1\">",
"      Chertow GM, Johansen KL, Lew N, et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000; 57:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/2\">",
"      Rocco MV, Paranandi L, Burrowes JD, et al. Nutritional status in the HEMO Study cohort at baseline. Hemodialysis. Am J Kidney Dis 2002; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/3\">",
"      2005 Annual Report: ESRD clinical performance measures project. Am J Kidney Dis 2006; 48(Suppl 2):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/4\">",
"      Combe C, McCullough KP, Asano Y, et al. Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): nutrition guidelines, indicators, and practices. Am J Kidney Dis 2004; 44:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/5\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/6\">",
"      Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996; 7:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/7\">",
"      Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/8\">",
"      Port FK, Pisoni RL, Bragg-Gresham JL, et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif 2004; 22:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/9\">",
"      Lindsay RM, Spanner E, Heidenheim RP, et al. Which comes first, Kt/V or PCR--chicken or egg? Kidney Int Suppl 1992; 38:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/10\">",
"      Lindsay RM, Nesrallah G, Suri R, et al. Is more frequent hemodialysis beneficial and what is the evidence? Curr Opin Nephrol Hypertens 2004; 13:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/11\">",
"      Davies SJ, Phillips L, Griffiths AM, et al. Analysis of the effects of increasing delivered dialysis treatment to malnourished peritoneal dialysis patients. Kidney Int 2000; 57:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/12\">",
"      Mitch WE, Maroni BJ. Factors causing malnutrition in patients with chronic uremia. Am J Kidney Dis 1999; 33:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/13\">",
"      Riella MC. Malnutrition in dialysis: malnourishment or uremic inflammatory response? Kidney Int 2000; 57:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/14\">",
"      Chazot C, Laurent G, Charra B, et al. Malnutrition in long-term haemodialysis survivors. Nephrol Dial Transplant 2001; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/15\">",
"      Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/16\">",
"      Bossola M, Tazza L, Giungi S, Luciani G. Anorexia in hemodialysis patients: an update. Kidney Int 2006; 70:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/17\">",
"      Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int 1981; 19:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/18\">",
"      Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int 1994; 46:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/19\">",
"      Kaplan AA, Halley SE, Lapkin RA, Graeber CW. Dialysate protein losses with bleach processed polysulphone dialyzers. Kidney Int 1995; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/20\">",
"      Sherman RA, Cody RP, Rogers ME, Solanchick JC. Interdialytic weight gain and nutritional parameters in chronic hemodialysis patients. Am J Kidney Dis 1995; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/21\">",
"      Lim VS, Ikizler TA, Raj DS, Flanigan MJ. Does hemodialysis increase protein breakdown? Dissociation between whole-body amino acid turnover and regional muscle kinetics. J Am Soc Nephrol 2005; 16:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/22\">",
"      Gutierrez A, Alvestrand A, Wahren J, Bergstr&ouml;m J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/23\">",
"      Uribarri J, Levin NW, Delmez J, et al. Association of acidosis and nutritional parameters in hemodialysis patients. Am J Kidney Dis 1999; 34:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/24\">",
"      Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/25\">",
"      Pickering WP, Price SR, Bircher G, et al. Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 2002; 61:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/26\">",
"      Mamoun AH. Anorexia in patients with chronic renal failure--progress towards understanding the molecular basis. Nephrol Dial Transplant 1998; 13:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/27\">",
"      Daschner M, T&ouml;nshoff B, Blum WF, et al. Inappropriate elevation of serum leptin levels in children with chronic renal failure. European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. J Am Soc Nephrol 1998; 9:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/28\">",
"      Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998; 9:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/29\">",
"      Fouque D, Juillard L, Lasne Y, et al. Acute leptin regulation in end-stage renal failure: the role of growth hormone and IGF-1. Kidney Int 1998; 54:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/30\">",
"      Cheng LT, Tang W, Wang T. Strong association between volume status and nutritional status in peritoneal dialysis patients. Am J Kidney Dis 2005; 45:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/31\">",
"      Jones CH, Wells L, Stoves J, et al. Can a reduction in extracellular fluid volume result in increased serum albumin in peritoneal dialysis patients? Am J Kidney Dis 2002; 39:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/32\">",
"      Dumler F. Hypoalbuminemia is a marker of overhydration in chronic maintenance patients on dialysis. ASAIO J 2003; 49:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/33\">",
"      Misra M, Nolph KD, Khanna R, et al. Retrospective evaluation of renal kt/V(urea) at the initiation of long-term peritoneal dialysis at the University of Missouri: relationships to longitudinal nutritional status on peritoneal dialysis. ASAIO J 2003; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/34\">",
"      Cano N, Labastie-Coeyrehourq J, Lacombe P, et al. Perdialytic parenteral nutrition with lipids and amino acids in malnourished hemodialysis patients. Am J Clin Nutr 1990; 52:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/35\">",
"      Ohkawa S, Kaizu Y, Odamaki M, et al. Optimum dietary protein requirement in nondiabetic maintenance hemodialysis patients. Am J Kidney Dis 2004; 43:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/36\">",
"      Dialysis Outcomes Quality Initiative Guidelines. Clinical practice guidelines for nutrition in chronic renal failure. Guideline 15. Am J Kidney Dis 2000. Am J Kidney Dis 2000; 35(Suppl 2):S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/37\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/38\">",
"      Dialysis Outcomes Quality Initiative Guidelines. Clinical practice guidelines for nutrition in chronic renal failure. Guideline 16. Am J Kidney Dis 2000. Am J Kidney Dis 2000; 35(Suppl 2):S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/39\">",
"      Veeneman JM, Kingma HA, Boer TS, et al. The metabolic response to ingested protein is normal in long-term hemodialysis patients. Am J Kidney Dis 2004; 43:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/40\">",
"      Slomowitz LA, Monteon FJ, Grosvenor M, et al. Effect of energy intake on nutritional status in maintenance hemodialysis patients. Kidney Int 1989; 35:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/41\">",
"      Rothstein RD, Alavi A. The evaluation of the patient with gastroparesis secondary to insulin-dependent diabetes mellitus. J Nucl Med 1992; 33:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/42\">",
"      Grodstein, G, Harrison, A, Roberts, C, et al. Impaired gastric emptying in hemodialysis patients (abstract). Kidney Int 1979; 16:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/43\">",
"      De Schoenmakere G, Vanholder R, Rottey S, et al. Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients. Nephrol Dial Transplant 2001; 16:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/44\">",
"      Bateman DN, Gokal R, Dodd TR, Blain PG. The pharmacokinetics of single doses of metoclopramide in renal failure. Eur J Clin Pharmacol 1981; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/45\">",
"      Tack J, Janssens J, Vantrappen G, et al. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992; 103:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/46\">",
"      Silang R, Regalado M, Cheng TH, Wesson DE. Prokinetic agents increase plasma albumin in hypoalbuminemic chronic dialysis patients with delayed gastric emptying. Am J Kidney Dis 2001; 37:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/47\">",
"      Brown CK, Khanderia U. Use of metoclopramide, domperidone, and cisapride in the management of diabetic gastroparesis. Clin Pharm 1990; 9:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/48\">",
"      Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/49\">",
"      Ross EA, Koo LC. Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients. Am J Kidney Dis 1998; 31:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/50\">",
"      Kopple JD. Therapeutic approaches to malnutrition in chronic dialysis patients: the different modalities of nutritional support. Am J Kidney Dis 1999; 33:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/51\">",
"      Caglar K, Fedje L, Dimmitt R, et al. Therapeutic effects of oral nutritional supplementation during hemodialysis. Kidney Int 2002; 62:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/52\">",
"      Stratton RJ, Bircher G, Fouque D, et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2005; 46:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/53\">",
"      Lacson E Jr, Wang W, Zebrowski B, et al. Outcomes associated with intradialytic oral nutritional supplements in patients undergoing maintenance hemodialysis: a quality improvement report. Am J Kidney Dis 2012; 60:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/54\">",
"      Wright S, Weiner DE. Oral nutritional supplement use in dialysis patients: full speed ahead? Am J Kidney Dis 2012; 60:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/55\">",
"      Cheu C, Pearson J, Dahlerus C, et al. Association between oral nutritional supplementation and clinical outcomes among patients with ESRD. Clin J Am Soc Nephrol 2013; 8:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/56\">",
"      Eustace JA, Coresh J, Kutchey C, et al. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int 2000; 57:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/57\">",
"      Abras E, Walser M. Nitrogen utilization in uremic patients fed by continuous nasogastric infusion. Kidney Int 1982; 22:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/58\">",
"      Wolfson M, Jones MR, Kopple JD. Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 1982; 21:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/59\">",
"      McCann L, Feldman C, Hornberger J, et al. Effect of intradialytic parenteral nutrition on delivered Kt/V. Am J Kidney Dis 1999; 33:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/60\">",
"      Pupim LB, Flakoll PJ, Brouillette JR, et al. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest 2002; 110:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/61\">",
"      Foulks CJ. An evidence-based evaluation of intradialytic parenteral nutrition. Am J Kidney Dis 1999; 33:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/62\">",
"      Capelli JP, Kushner H, Camiscioli TC, et al. Effect of intradialytic parenteral nutrition on mortality rates in end-stage renal disease care. Am J Kidney Dis 1994; 23:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/63\">",
"      Wolfson M. Use of intradialytic parenteral nutrition in hemodialysis patients. Am J Kidney Dis 1994; 23:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/64\">",
"      Cano NJ, Fouque D, Roth H, et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/65\">",
"      Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/66\">",
"      Rocco MV, Dwyer JT, Larive B, et al. The effect of dialysis dose and membrane flux on nutritional parameters in hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/67\">",
"      Jager KJ, Merkus MP, Huisman RM, et al. Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2001; 12:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/68\">",
"      Ziegler TR, Lazarus JM, Young LS, et al. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 1991; 2:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/69\">",
"      Ikizler TA, Wingard RL, Breyer JA, et al. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 1994; 46:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/70\">",
"      Johannsson G, Bengtsson BA, Ahlm&eacute;n J. Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999; 33:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/71\">",
"      Feldt-Rasmussen B, Lange M, Sulowicz W, et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/72\">",
"      Ikizler TA, Wingard RL, Flakoll PJ, et al. Effects of recombinant human growth hormone on plasma and dialysate amino acid profiles in CAPD patients. Kidney Int 1996; 50:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/73\">",
"      Garibotto G, Barreca A, Russo R, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/74\">",
"      Iglesias P, D&iacute;ez JJ, Fern&aacute;ndez-Reyes MJ, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis 1998; 32:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/75\">",
"      Ikizler TA, Wingard RL, Hakim RM. Interventions to treat malnutrition in dialysis patients: the role of the dose of dialysis, intradialytic parenteral nutrition, and growth hormone. Am J Kidney Dis 1995; 26:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/76\">",
"      Fouque D, Peng SC, Shamir E, Kopple JD. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int 2000; 57:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/77\">",
"      Hansen TB, Gram J, Jensen PB, et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000; 53:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/78\">",
"      Garibotto G, Barreca A, Sofia A, et al. Effects of growth hormone on leptin metabolism and energy expenditure in hemodialysis patients with protein-calorie malnutrition. J Am Soc Nephrol 2000; 11:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/79\">",
"      Kotzmann H, Schmidt A, Lercher P, et al. One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients. Nephron Clin Pract 2003; 93:C75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/80\">",
"      Kopple JD, Cheung AK, Christiansen JS, et al. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/81\">",
"      Gasc&oacute;n A, Belvis JJ, Berisa F, et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/82\">",
"      Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/83\">",
"      Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002; 58:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/84\">",
"      Atkin-Thor E, Goddard BW, O'Nion J, et al. Hypogeusia and zinc depletion in chronic dialysis patients. Am J Clin Nutr 1978; 31:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/85\">",
"      Burge JC, Park HS, Whitlock CP, Schemmel RA. Taste acuity in patients undergoing long-term hemodialysis. Kidney Int 1979; 15:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/86\">",
"      Hylander B, Barkeling B, R&ouml;ssner S. Eating behavior in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1992; 20:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/87\">",
"      Bouma SF, Dwyer JT. Glucose absorption and weight change in 18 months of continuous ambulatory peritoneal dialysis. J Am Diet Assoc 1984; 84:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/88\">",
"      Aguirre Galindo BA, Prieto Fierro JG, Cano P, et al. Effect of polymeric diets in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2003; 23:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/89\">",
"      Gonz&aacute;lez-Espinoza L, Guti&eacute;rrez-Ch&aacute;vez J, del Campo FM, et al. Randomized, open label, controlled clinical trial of oral administration of an egg albumin-based protein supplement to patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2005; 25:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/90\">",
"      Teixid&oacute;-Planas J, Ortiz A, Coronel F, et al. Oral protein-energy supplements in peritoneal dialysis: a multicenter study. Perit Dial Int 2005; 25:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/91\">",
"      Boudville N. Oral nutritional supplementation in peritoneal dialysis patients--does it work? Perit Dial Int 2005; 25:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/92\">",
"      Bruno M, Bagnis C, Marangella M, et al. CAPD with an amino acid dialysis solution: a long-term, cross-over study. Kidney Int 1989; 35:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/93\">",
"      Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/94\">",
"      Jones M, Hagen T, Boyle CA, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998; 32:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/95\">",
"      Wolfson M, Jones M. Intraperitoneal nutrition. Am J Kidney Dis 1999; 33:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/96\">",
"      Qamar IU, Secker D, Levin L, et al. Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis. Perit Dial Int 1999; 19:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/97\">",
"      Tjiong HL, van den Berg JW, Wattimena JL, et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/98\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/99\">",
"      Ramage IJ, Geary DF, Harvey E, et al. Efficacy of gastrostomy feeding in infants and older children receiving chronic peritoneal dialysis. Perit Dial Int 1999; 19:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/100\">",
"      Stein A, Moorhouse J, Iles-Smith H, et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997; 52:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/101\">",
"      Goodship TH. What is the relationship between metabolic acidosis and nutritional status in dialysis patients? Am J Kidney Dis 1998; 31:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/3/9274/abstract/102\">",
"      Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005; 16:2111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1856 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-F2EAE850DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9274=[""].join("\n");
var outline_f9_3_9274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Drug toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nutritional supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dialysis prescription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recombinant human growth hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Correction of acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MALNUTRITION IN CONTINUOUS AMBULATORY PERITONEAL DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Amino acid dialysate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Enteral tube feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1856\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1856|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/49/20253\" title=\"figure 1A\">",
"      Risk of mortality among dial pts according to baseline albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/37/20061\" title=\"figure 1B\">",
"      Risk of mortality among hemodial pts according to serum albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/39/12926\" title=\"figure 2\">",
"      Energy intake nitrogen balance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=related_link\">",
"      Diabetic autonomic neuropathy of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10614?source=related_link\">",
"      Dialysis in diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20986?source=related_link\">",
"      Gastrointestinal disease in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33591?source=related_link\">",
"      Leptin and end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13929?source=related_link\">",
"      Pathogenesis of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=related_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_3_9275="Syncope high risk";
var content_f9_3_9275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors that lead to stratification as high risk for adverse outcome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abnormal ECG*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of cardiac disease, especially presence of heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistently low blood pressure (systolic &lt;90 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shortness of breath with event or during evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematocrit &lt;30 (if obtained)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Older age and associated comorbidities&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of sudden cardiac death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * ECG abnormalities including acute ischemia or infarction, arrhythmias, or significant conduction abnormalities.",
"     <br>",
"      &bull; Different studies use different ages to determine elevated risk. Age is likely a continuous variable&nbsp;that acts as a&nbsp;marker for&nbsp;the cardiovascular health of the patient.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9275=[""].join("\n");
var outline_f9_3_9275=null;
var title_f9_3_9276="Causes of sideroblastic anemia";
var content_f9_3_9276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification and causes of the sideroblastic anemias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Congenital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Non-syndromic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        X-linked (XLSA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mitochondrial transporter SLC25A38 defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glutaredoxin 5 deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Erythropoietic protoporphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Syndromic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        X-linked with ataxia (XLSA/A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myopathy, lactic acidosis and sideroblastic anemia (MLASA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pearson marrow-pancreas syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thiamine responsive megaloblastic anemia (TRMA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Syndromic or non-syndromic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Autosomal of unknown cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sporadic congenital of unknown cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Clonal/neoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Refractory anemia with ring sideroblasts (RARS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Refractory anemia with ring sideroblasts and thrombocytosis (RARS-T)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Metabolic/reversible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcoholism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drugs (eg, isoniazid, chloramphenicol, linezolid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Copper deficiency (zinc toxicity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypothermia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9276=[""].join("\n");
var outline_f9_3_9276=null;
var title_f9_3_9277="Sources of lead exposure";
var content_f9_3_9277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources of lead exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Occupational",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Plumbers, pipe fitters",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lead miners",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lead smelters and refiners",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Auto repairers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glass manufacturers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Shipbuilders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Printers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Plastic manufacturers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Police officers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Steel welders or cutters",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Construction workers (especially renovation and rehabilitation)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rubber product manufacturers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gas station attendants (past exposure)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Battery manufacturers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Battery recyclers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bridge reconstruction workers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Firing range instructors",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Homes/Buildings",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lead-containing paint/pigment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Soil/dust near lead industries, roadways, lead-painted homes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Plumbing leachate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ceramic ware (especially imported)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leaded gasoline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vinyl miniblinds*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hobbies and related activities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glazed pottery making",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Target shooting at firing ranges",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lead soldering (eg, electronics)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Painting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Preparing lead shot, fishing sinkers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stained-glass making",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Car or boat repair",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Home remodeling",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other sources",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Folk remedies (Mexican: azarcon, greta, alarcon, coral liga, Maria Luisa, rueda; Asian: ba-baw-san, bali goli, chuifong, ghasard, kandu, tokuwan)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tobacco smoking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cosmetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Moonshine whiskey",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gasoline \"huffing\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ayurvedic medications",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Made outside the United States and purchased before 1997.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from www.atsdr.cdc.gov/csem/lead/pbwhoisat_risk2.htm and www.atsdr.cdc.gov/csem/lead/pbwhere_found2.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9277=[""].join("\n");
var outline_f9_3_9277=null;
var title_f9_3_9278="Theophylline to treat asthma";
var content_f9_3_9278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Addition of theophylline to inhaled glucocorticoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean frequency of symptoms in 21 children with asthma who were receiving a constant dose of chlorofluorocarbon (CFC) beclomethasone dipropionate and were treated in randomized sequence for four weeks each with placebo (P) and theophylline (T). The dose of theophylline was individualized to achieve a peak serum concentration of 10 to 20 &micro;g per milliliter. The dose of CFC beclomethasone averaged 550 &micro;g daily. Nocturnal symptoms of cough, wheezing, or dyspnea that disturbed sleep were recorded each morning, and symptoms that interfered with normal activity and any episodes of cough or wheezing during the day were recorded each evening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Weinberger M, Hendeles L, N Engl J Med 1996; 334:1380.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9278=[""].join("\n");
var outline_f9_3_9278=null;
var title_f9_3_9279="Rash in secondary syphilis";
var content_f9_3_9279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secondary syphilis: Rash",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rash of secondary syphilis characteristically involves the palms and soles. It may have a variety of appearances but is usually pigmented and macular.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles B Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_3_9279=[""].join("\n");
var outline_f9_3_9279=null;
